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R59X mice, we hypothesized that mutant mice would exhibit underlying molecular and functional alterations
in proteins involved in regulating the E:I balance. Indeed, we observed a specific decrease in membrane-
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to human CDD patients, thus validating R59X mice as a relevant model to test potential therapeutics in CDD.
Indeed, IEM-1460 significantly rescued deficits in social behavior, short-term memory, and latency to seizure
while cannabidiol significantly rescued deficits in short and long-term memory and latency to seizure. These
results verify that blocking increased GluA2-lacking AMPARs may be a successful therapeutic strategy in
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ABSTRACT 
 
AMPA RECEPTOR DYSREGULATION AND THERAPEUTIC INTERVENTIONS IN A 
MOUSE MODEL OF CDKL5 DEFICIENCY DISORDER 
Madhumita Yennawar 
Frances E. Jensen 
CDKL5 Deficiency Disorder (CDD) is a rare disease that presents as a set of 
neurological deficits including early-life epilepsy, intellectual disability, and autistic-like 
behaviors. It results from pathogenic mutations in the gene for cyclin-dependent kinase-
like 5 (CDKL5), a protein that is highly expressed in brain. There is no cure for CDD and 
seizures in this disorder are typically resistant to traditional anti-epileptic drugs, although 
some patients respond well to cannabidiol. However, underlying mechanisms of what 
causes hyperexcitability and neurological deficits in CDD is poorly understood. We 
investigated the novel Cdkl5R59X mouse (R59X), and observed that mutant mice have 
social interaction and memory deficits, and decreased latency to seizure after 
administration of pentylenetetrazol. Given the observed behavioral alterations and 
hyperexcitability in R59X mice, we hypothesized that mutant mice would exhibit 
underlying molecular and functional alterations in proteins involved in regulating the E:I 
balance. Indeed, we observed a specific decrease in membrane-bound AMPA receptor 
(AMPAR) subunit GluA2 as well as decreased GluA2:GluA1 in the hippocampus of 
R59X mice, suggesting an increase in hippocampal GluA2-lacking AMPARs, which are 
calcium permeable and have significant roles in regulating neuronal plasticity and 
excitability. Indeed, decreased hippocampal GluA2 was accompanied by inward 
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rectification of AMPAR currents in whole-cell patch recordings from hippocampal CA1 
neurons, indicative of an increased population of functional GluA2-lacking AMPARs, and 
elevated early-phase long-term potentiation at Schaffer collateral-CA1 synapses. Finally, 
we evaluated the therapeutic potential of GluA2-lacking AMPAR blocker IEM-1460 as 
well as cannabidiol to observe 1) whether blocking increased hippocampal GluA2-
lacking AMPARs would attenuate behavioral alterations and hyperexcitability in R59X 
mice and 2) whether cannabidiol shows therapeutic efficacy in R59X mice similar to 
human CDD patients, thus validating R59X mice as a relevant model to test potential 
therapeutics in CDD. Indeed, IEM-1460 significantly rescued deficits in social behavior, 
short-term memory, and latency to seizure while cannabidiol significantly rescued 
deficits in short and long-term memory and latency to seizure. These results verify that 
blocking increased GluA2-lacking AMPARs may be a successful therapeutic strategy in 
CDD, and that both IEM-1460 and cannabidiol may attenuate hyperexcitability as well as 
autistic-like behaviors and memory deficits in CDD.  
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CHAPTER 1- Introduction 
Overview 
CDKL5 Deficiency Disorder (CDD) is a rare disease that is marked by a constellation of 
neurological deficits including early-life epilepsy, severe intellectual disability, and 
autistic behaviors. It is caused by pathogenic mutations in the gene for cyclin-dependent 
kinase-like 5 (CDKL5), a serine-threonine kinase that is highly expressed in the brain 
(Kilstrup-Nielsen et al., 2012; Zhou et al., 2017). CDKL5 is reported to interact with 
several nuclear and cytoplasmic proteins that modulate cellular processes ranging from 
gene regulation (Mari et al., 2005; Kameshita et al., 2008) to synaptic stability (Ricciardi 
et al., 2012) and microtubule dynamics (Baltussen et al., 2018; Munoz et al., 2018). 
Animal models of CDD have learning and memory impairments and autistic-like 
behavioral deficits, yet they exhibit inconsistencies in some behavioral phenotypes, 
dendritic spine abnormalities, and signaling pathways. However, as CDKL5 has 
repeatedly been found to localize to dendrites and loss of CDKL5 affects synaptic 
function, it is possible that it regulates proteins involved in the excitatory:inhibitory 
balance. Indeed, alterations neurotransmitter receptors and signaling are frequently 
observed in other neurodevelopmental disorders involving intellectual disability, autism, 
and epilepsy.  
Here we investigated a novel model of CDD, the Cdkl5R59X (R59X) mouse. We 
hypothesized that R59X mice would display autistic-like behaviors, learning and memory 
impairments, and increased seizure susceptibility consistent with features of the human 
disease. Furthermore, we predicted that R59X mice would exhibit underlying alterations 
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in membrane-bound glutamate receptor subunits, and that pharmacologically targeting 
the alterations would reduce seizure susceptibility and other behavioral deficits in these 
mice. R59X mice display key phenotypes reflective of the human disorder, including 
deficits in social interaction, impaired short-term and long-term memory, and subtle 
hyperexcitability that manifests as decreased latency to behavioral seizures (Chapter 2). 
We also found evidence of increased GluA2-lacking AMPA receptors in the adult R59X 
hippocampus (Chapter 3) that was accompanied with functional changes in hippocampal 
slice recordings (Chapter 4). Finally, we assessed the therapeutic efficacy of GluA2-
lacking AMPA receptor blocker IEM-1460 (Chapter 5) and the experimental therapeutic 
cannabidiol (CBD; Chapter 6) in attenuating behavioral deficits in R59X mice.  
I.  CDKL5 Deficiency Disorder 
CDKL5 Deficiency Disorder (CDD) results from pathogenic mutations in the X-linked 
gene for cyclin-dependent kinase-like 5 (CDKL5), a serine-threonine kinase that is highly 
expressed in the brain, particularly in neurons (Montini et al., 1998; Lin et al., 2005; 
Rusconi et al., 2008; Chen et al., 2010). CDD was first characterized in early 2000s 
when two unrelated female patients presented with identical phenotypes, consisting of 
early-onset severe infantile spasms, developmental arrest, hypsarrhythmia, and mental 
retardation and were subsequently found to possess mutations in CDKL5, initially 
termed STK9 for serine-threonine kinase 9 (Kalscheuer et al., 2003). Although the gene 
for CDKL5 is on the X chromosome, CDD affects both males and females (Kilstrup-
Nielsen et al., 2012). Originally the disorder was thought to be a variant of Rett 
Syndrome (RTT), but studies soon supported the conclusion that it is a separate 
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neurodevelopmental disease with a distinct clinical profile, consisting mainly of seizure 
onset before 3 months of age, severely impaired language and gross motor skills, rather 
than the developmental regression commonly observed in RTT  (Kalscheuer et al., 2003; 
Weaving et al., 2004; Fehr et al., 2015).  
Seizures are an early presentation in patients with CDD and typically can be described 
as progressing through three stages. Stage I, early epilepsy, is characterized by brief but 
frequent seizures, typically infantile spasms, that occur daily and often greater than five 
times a day (Bahi-Buisson et al., 2008). At this stage patients are typically treated by the 
conventional antiepileptic drugs (AEDs) valproate or vigabatrin alone or in combination. 
While treatment is often effective initially, most patients experience relapse of seizures 
after a honeymoon period that lasts anywhere from 3-30 months. Stage II of seizures is 
marked by epileptic encephalopathy, which is an “epileptic condition characterized by 
epileptiform abnormalities associated with progressive cerebral dysfunction” (Khan and 
Baradie, 2012), but in CDD consists of infantile spasms, tonic seizures and 
hypsarrhythmia. Infantile spasms occur as clusters of contractions of the muscles in the 
neck, trunk, arms, and legs, and are often treated with corticosteroids with varied 
success (Pavone et al., 2013). Stage III manifests as late multifocal and myoclonic 
epilepsy, in which seizure types can vary from tonic seizures to spasms, myoclonia and 
absence seizures. (Bahi-Buisson et al., 2008) 
As above, seizures in CDD are often refractory to traditional anti-epileptic drugs and are 
extremely difficult to manage for patients with CDD and their families. Because of this, 
many have recently turned to alternatives such as the experimental therapeutic 
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cannabidiol (CBD) for its purported therapeutic effects in children with early-life epilepsy 
(Porter et al., 2013). This has resulted in the first double-blind study where CBD was 
found to be effective as an add-on therapy in reducing monthly seizure frequency in 
CDD and other neurodevelopmental disorders with early-life epilepsy such as Doose 
syndrome and Dravet syndrome (Devinsky et al., 2018a., 2018b.). Additionally, the FDA 
has recently approved Epidiolex, purified CBD, to treat Lennox-Gastaut Syndrome and 
Dravet Syndrome (Corroon et al., 2018).  
In addition to seizures being a major component of the disorder in most cases, children 
with CDD also exhibit severe neurodevelopmental delay. Gross motor hypotonia and 
poor eye contact are observed as early as a few months of age, and within 2-3 years 
patients exhibit severe intellectual disability, hypotonia (Bahi-Buisson et al., 2008). 
Additionally, many patients display poor social interaction, avoidance of eye contact and 
poor eye fixation, and stereotyped hand movements which are considered autistic 
features (Bahi-Buisson et al, 2008). According to the CDKL5 Forum, over 1,600 patients 
with CDKL5 mutations have been documented worldwide to date 
(https://www.cdkl5forum.org/). Pathogenic mutations occur anywhere along the gene 
and symptoms can range in severity (Kilstrup-Nielsen et al., 2012).  
Although the number of patients identified with CDD is growing, how pathogenic 
mutations in CDKL5 result in CDD is still relatively unclear. Normally, CDKL5 is 
particularly enriched in the hippocampus and cerebral cortex (Rusconi et al., 2008; 
Wang et al., 2012; Schroeder et al., 2018), brain regions that are critical for learning and 
memory and higher cognitive functions (Brown and Aggleton, 2001). In rodents, 
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expression of CDKL5 is low during embryonic time points, but is upregulated significantly 
soon after birth and remains steady throughout adulthood (Rusconi et al., 2008; Chen et 
al., 2010; Nawaz et al., 2016; Schroeder et al., 2018). Several isoforms of CDKL5 have 
been reported, some of which are predominantly found in the human and mouse brain 
(Hector et al., 2016, 2017), but the importance of the splice isoforms remains unclear. 
Recent studies have probed into potential roles of CDKL5 in neuronal function, and the 
following sections discuss what is currently known about CDKL5, its activity in neurons, 
and its interacting partners.  
Regulation of CDKL5 subcellular distribution and activity 
Expression of CDKL5 is high in neurons and relatively low in glia (Rusconi et al., 2008; 
Chen et al., 2010). Although CDKL5 localizes to both cytoplasmic and nuclear 
compartments in neurons, it appears to be primarily cytoplasmic (Rusconi et al., 2008; 
Chen et al., 2010; Wang et al., 2012; Ricciardi et al., 2012). However, the relative 
proportion of CDKL5 that localizes to the nuclear compartment increases over brain 
development (Rusconi et al., 2008). In the nucleus, CDKL5 is reported to localize to 
nuclear speckles, which are centers of RNA splicing and processing  (Ricciardi et al., 
2009). In cell culture, CDKL5 is initially found in growth cones that mediate neurite 
outgrowth (Chen et al., 2010). As neurons mature, CDKL5 localizes to dendritic spines 
and is particularly enriched at the post-synaptic density (PSD) where it interacts with 
excitatory synaptic proteins (Ricciardi et al., 2012; Zhu et al., 2013; Schroeder et al., 
2018). Recruitment of CDKL5 to the PSD is achieved through its interaction with post-
synaptic density protein 95 (PSD-95), which anchors it at the synapse (Zhu et al., 2013). 
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Splice variants of CDKL5 could also play a role in localization, as some variants have 
distinct C-terminal regions that may result in targeting of the kinase to specific 
subcellular locations (Rusconi et al., 2008; Chen et al., 2010).  
Phosphorylation of CDKL5 itself may also play a role in its activity and subcellular 
localization, as, CDKL5 can be phosphorylated at Ser308 by DYRK1A, which causes it 
to localize to the cytoplasm in Neuro2a cells (Oi et al., 2017), as well as at an unknown 
site by BDNF signaling (Chen et al., 2010). Finally, dephosphorylation of CDKL5 occurs 
through activity of protein phosphatase 1 (PP1) which induces proteasomal degradation 
of CDKL5 (La Montanara et al., 2015). Thus, activity, localization and stability of CDKL5 
may be regulated through phosphorylation and dephosphorylation.   
Role of CDKL5 in synapse stability  
Synapses mediate excitatory and inhibitory neurotransmission between neurons and are 
stabilized by PSD proteins (Okabe, 2007), many of which are implicated in 
neurodevelopmental disorders (Kaizuka and Takumi, 2018). Indeed, abnormal dendritic 
morphology is observed in numerous neurodevelopmental disorders  (Martínez-
Cerdeño, 2017), including CDD. CDKL5 knock-out (KO) mice have a significant 
reduction in spine density and number of mature spines in cortex layer V pyramidal 
neurons, dentate gyrus granule cells, and hippocampal CA1 pyramidal neurons  (Della 
Sala et al., 2016; Trazzi et al., 2018). Furthermore, in cell culture, CDKL5 
downregulation by RNAi resulted in decreased excitatory synaptic markers such as 
PSD-95, as well as decreased frequency of miniature EPSCs, suggesting an overall 
reduction in excitatory synapses (Ricciardi et al., 2012; Zhu et al., 2013). In contrast, 
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however, conditional KO of CDKL5 in excitatory neurons in the cortex and hippocampus 
results in significantly increased PSD-95 (Schroeder et al., 2018) and a trend toward 
increased spine density and volume (Tang et al., 2017), perhaps due to selective gene 
deletion from excitatory neurons in the hippocampus and cortex rather than constitutively 
ablating CDKL5 in all cell types and brain regions. These results suggest that while 
CDKL5 likely plays a role in individual synapse stability, neuronal excitability and 
function in CDD are also modulated by circuit-level changes in connectivity or neuronal 
wiring. 
As mentioned previously, CDKL5 is anchored at the PSD through interaction with PSD-
95 (Zhu et al., 2013), a critical scaffolding protein at excitatory synapses involved with 
regulating the organization of neurotransmitter receptors and other molecules that 
modulate synaptic activity (Chen et al., 2011, 2015). The CDKL5-PSD-95 interaction 
enables CDKL5 to interact with downstream effector molecules, such as netrin-G1 ligand 
(NGL-1) (Ricciardi et al., 2012), a synaptic adhesion protein that is also implicated in 
neurodevelopmental disorders (Maussion et al., 2017). CDKL5 phosphorylates NGL-1 
and promotes its interaction with PSD-95, which supports dendritic spine stability 
(Ricciardi et al., 2012). Additionally, the CDKL5-PSD-95 interaction is regulated by 
activity-dependent post-translational palmitoylation of PSD-95 (Zhu et al., 2013; El-
Husseini et al., 2002), and is thought to facilitate neurotransmitter receptor clustering at 
the synapse (Saneyoshi and Hayashi, 2014; Chen et al., 2015). This suggests that 
CDKL5 has a critical role in synaptic function and plasticity.  
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Role of CDKL5 in synaptic function 
CDKL5 deficiency results in functional changes at the neuronal level. Cdkl5 knockdown 
in primary hippocampal neurons significantly reduced frequency and amplitude of mini 
excitatory post-synaptic potentials (mEPSCs; Ricciardi et al, 2012), which are 
spontaneous events that result from quantal release of neurotransmitters from the 
presynaptic neuron (Pinheiro and Mulle, 2008). The frequency of mEPSCs are 
dependent on presynaptic release of neurotransmitters from vesicles whereas the 
amplitude of mEPSCs depends on activation of post-synaptic receptors (Pinheiro and 
Mulle, 2008). Thus, a change in both frequency and amplitude of mEPSCs suggests that 
loss of CDKL5 results in alterations in both presynaptic and postsynaptic function. A 
decrease in amplitude of mEPSCs was also observed in neurons after shRNA knock-
down of CDKL5 (Tramarin et al., 2018), supporting postsynaptic alterations. However, in 
CDKL5 KO mice, mEPSC amplitude was not altered in layer V pyramidal cells although 
mEPSC frequency was significantly decreased (Della Sala et al., 2016), suggesting a 
presynaptic deficit. Furthermore, loss of CDKL5 in excitatory forebrain neurons in the 
hippocampus and cortex resulted in increased frequency of mEPSCs without a change 
in amplitude in hippocampus CA1 (Tang et al., 2017), suggesting an increase in 
presynaptic function.  
Studies investigating synaptic plasticity in mouse models of CDD have been limited. One 
group found that CDKL5 KO mice exhibit impaired long-term potentiation in the cortex 
layer II/III (Della Sala et al., 2016) while another showed elevated LTP in CDKL5 KO 
hippocampus (Okuda et al., 2017). The contrasting results from mEPSC and LTP 
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recordings are difficult to reconcile, but they may be due to region-specific effects of loss 
of function of CDKL5.  
Role of CDKL5 in neuronal migration and axon growth 
RNAi of CDKL5 in neural progenitor cells causes abnormal migration of layer II-III 
pyramidal neurons in the rodent brain (Chen et al., 2010; Ricciardi et al., 2012), 
potentially due to impaired microtubule dynamics. CDKL5 is reported to interact with 
IQGAP1, a molecule that regulates cell migration and polarity, and promote association 
of IQGAP with Rac1, a small GTPase that is part of a family of proteins that are involved 
with cell morphology and actin dynamics, and CLIP170, a microtubule-associated 
protein (Barbiero et al., 2017). In cultured neurons, CDKL5 is found to modulate axon 
development by phosphorylating Shootin1, a regulator of axon outgrowth that co-
localizes with CDKL5 in growth cones during early neuronal development (Nawaz et al., 
2016). Silencing or overexpressing CDKL5 results in neurons with multiple axons, which 
authors attributed to dysregulation of Shootin1 phosphorylation. However, loss of 
function of CDKL5 does not affect axon formation (Chen et al., 2010; Nawaz et al., 
2016), suggesting that CDKL5, though important for normal axon development, is likely 
not critical for axon formation.  
Role of CDKL5 in dendrites 
Dendritic abnormalities have been observed in numerous developmental disorders such 
as Fragile X Syndrome, Tuberous Sclerosis, epilepsy, and autism (Martínez-Cerdeño, 
2017). Neurite growth and dendritic arborization are severely compromised in cell culture 
after CDKL5 downregulation by RNAi (Chen et al., 2010). Dendritic abnormalities are 
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also observed in vivo, where in utero electroporation-induced silencing of CDKL5 causes 
reduced dendritic arborization (Chen et al., 2010), and in CDKL5 KO mice where total 
length of apical dendrites is reduced in the cortex and hippocampus (Amendola et al., 
2014) and in dentate gyrus (Fuchs et al., 2014). Reduced dendritic complexity is also 
observed in a conditional KO mouse where CDKL5 is absent in forebrain excitatory 
neurons (Tang et al., 2017). Interestingly, overexpression of CDKL5 in neuronal culture 
results in increased dendritic length (Chen et al., 2010), suggesting that CDKL5 
regulates and is sufficient for dendritic growth.  
Although the exact mechanism by which CDKL5 modulates dendritic growth is unknown, 
the kinase does form a protein complex with Rac1, a small GTPase that regulates actin 
dynamics. Furthermore, CDKL5 plays a key role in activation of Rac1 by brain-derived 
neurotrophic factor (BDNF)—downregulation of CDKL5 decreases Rac1 activation 
through BDNF and BDNF treatment causes an increased phosphorylation of CDKL5 that 
occurs before Rac1 activation. Thus, CDKL5 may be an upstream regulator of Rac1 
signaling, although it is still unclear if Rac1 is a direct substrate of CDKL5. CDKL5 may 
induce Rac1 activation through other signaling pathways such as the AKT/mTOR 
pathway or AKT/GSK-3b, both of which are dysregulated in CDKL5 KO mice (Wang et 
al., 2012; Fuchs et al., 2014) and regulate neuronal morphogenesis  (Kumar et al., 2005; 
Jin et al., 2012).  
Nuclear substrates of CDKL5 
There have been several reported nuclear substrates of CDKL5. In vitro, CDKL5 
phosphorylates DNA methyltransferase 1 (Dnmt1) (Kameshita et al., 2008), a nuclear 
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protein involved in cytosine methylation, gene silencing, and neurocognitive 
development  (Irwin et al., 2016). CDKL5 is also reported to weakly bind and 
phosphorylate Methyl-CpG-binding protein 2 (MeCP2) (Mari et al., 2005; Kameshita et 
al., 2008), a global transcriptional regulator implicated in Rett syndrome (Chahrour et al., 
2008). Neither MeCP2 nor Dnmt1 phosphorylation by CDKL5 have been observed in the 
brain, and downstream effects of abnormal MeCP2 or Dnmt1 phosphorylation in CDD 
have not been elucidated. Therefore, further experiments are needed to investigate 
whether they are true endogenous substrates of CDKL5. More recently, HDAC4 was 
found to be a substrate of CDKL5 both in vitro in SH-SY5Y cells and in vivo in knockout 
mice (Trazzi et al., 2016). HDAC4 is another transcriptional regulator that represses 
genes that are important for synaptic function, and its deficiency in mice and flies impairs 
learning and memory (Sando et al., 2012). Translocation of HDAC4 from the cytoplasm 
to the nucleus is regulated by its activity-dependent phosphorylation (Chawla et al., 
2003). Indeed, decreased phosphorylation of HDAC4 in neuronal precursor cells from 
CDKL5 KO mice caused abnormal cytoplasmic accumulation of HDAC4 (Trazzi et al., 
2016).  
Cytoplasmic substrates of CDKL5 
Two cytoplasmic substrates of CDKL5 have been identified in in vitro assays: NGL-1 
(Ricciardi et al., 2012) and Amphiphysin 1 (Amph1; Sekiguchi et al., 2013). NGL family 
proteins promote excitatory synapse development through interaction with PSD-95, cell 
adhesion molecules, and other proteins at the PSD (Kim et al., 2006; Woo et al., 2009). 
CDKL5 was found to phosphorylate NGL-1, promoting its interaction with PSD-95 and 
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consequently synaptic stability (Ricciardi et al., 2012). Amph1 is found at synapses, and 
is involved in clathrin-mediated endocytosis that is critical for actin polymerization 
(Yamada et al., 2007). Phosphorylation of NGL-1 and Amph1 by CDKL5 has not yet 
been verified in the brain. 
Several additional cytoplasmic substrates of CDKL5 have recently been identified 
through a study utilizing an analog-specific (AS) form of CDKL5 (AS-CDKL5) that is able 
to accept bulky ATP analogs and subsequently thiophosphorylate targets for 
identification. Through this method, CDKL5 appears to thiophosphorylate Rho guanine 
nucleotide exchange factor 2 (ARHGEF1), microtubule-associated protein 1S (MAP1S) 
and microtubule-associated protein RP/EB family member 2 (MAPRE2/EB2) in mouse 
brain lysate. CDKL5 also phosphorylates all three substrates in in vitro kinase assays in 
a time- and CDKL5 concentration-dependent manner (Baltussen et al., 2018). 
ARHGEF1, MAP1S, and EB2 all contain an RPXS* consensus motif, where X is any 
amino acid and S* is the phosphorylated serine. MAP1S contains two such sites, and 
CDKL5 phosphorylates MAP1S at both sites in vitro. A reduction in both EB2 Ser222 
and MAP1S Ser812 phosphorylation was observed in CDKL5 KO mouse cortex using 
validated phospho-specific antibodies. Decreases in ARHGEF2 Ser122 or MAP1S 
Ser786 phosphorylation were not able to be detected, perhaps due to decreased 
sensitivity of those antibodies. However, defects microtubule dynamics were observed in 
CDKL5 KO neurons that were attributed to abnormal MAP1S activity. Furthermore, 
CDKL5 phosphorylation of EB2 is inhibited by NMDAR activity, suggesting that it may 
play a role in activity-dependent circuit formation. Finally, although EB2 phosphorylation 
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was absent in CDD patient-derived neurons, abnormal phosphorylation of MAP1S and 
ARHGEF1 was not reported in these cells, calling into question whether these proteins 
are substrates of CDKL5 in humans.  
An independent report, which was co-published with the AS-CDKL5 study, used 
quantitative phosphoproteomics to identify three substrates of CDKL5: MAP1S, CEP131, 
and DLG5  (Muñoz et al., 2018). These proteins are regulators of microtubule and 
centrosome function and all contain the same RPXS* consensus motif that the 
substrates from the AS-CDKL5 report contain. Although mechanistic studies were not 
performed to investigate the consequence of CDKL5 phosphorylation of MAP1S, 
CEP131, or DLG5, all three substrates were validated in cells using FLAG pull-down 
assays. Further experiments are necessary to determine the functional consequence of 
CDKL5 phosphorylation of these proteins, but the identification of MAP1S as a substrate 
of CDKL5 in two independent studies is promising. Indeed, growing evidence suggests 
that dysregulated microtubule-associated proteins can contribute to neurodevelopmental 
disorders including intellectual disability and autism  (Lasser et al., 2018).  
Models of CDD 
Mouse models are excellent tool to study disease pathogenesis, molecular alterations, 
network function, plasticity, and circuit dynamics in CDD. Several constitutive and 
conditional knock-out (KO) models have been created to date that recapitulate core 
features of the human disease (Wang et al., 2012; Amendola et al., 2014; Tang et al., 
2017; Okuda et al., 2018). Interestingly, no CDD model exhibits visible spontaneous 
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convulsive seizures, although seizures are a strong feature in the human syndrome 
(Bahi-Buisson et al., 2008a.).  
Constitutive KO models 
Several mouse models of CDD exist to date, most of which are whole-body knock out 
models and have been tested for behavioral abnormalities. Some discrepancies in 
behavioral results do exist between CDKL5 KO models. For example, hypoactivity in the 
open field test was observed in two models (Amendola et al., 2014; Okuda et al., 2017) 
whereas the other two CDKL5 KO models showed hyperactivity  (Wang et al., 2012; 
Jhang et al., 2017) although different methods were used to characterized activity in 
these studies. Anxiety phenotypes have also been inconsistent between models, with 
one model showing increased anxiety (Okuda et al., 2018) and one showing decreased 
(Wang et al., 2012). The phenotypes that are consistently observed in all constitutive 
knock-out mouse models of CDD have been impaired motor coordination, social 
interaction, and learning and memory (Wang et al., 2012; Fuchs et al., 2014; Jhang et 
al., 2017; Okuda et al., 2018), highlighting the importance of normal CDKL5 function for 
these processes.  
Conditional KO models 
The Nex-cKO mouse is a conditional knock-out model where CDKL5 was removed from 
forebrain glutamatergic neurons, specifically those in the cortex and hippocampus (Tang 
et al., 2017). Interestingly, Nex-cKO mice do not exhibit alterations in activity, anxiety, 
motor coordination, or social behavior. They do, however, show deficits in hippocampal-
dependent learning and memory (Tang et al., 2017), suggesting that CDKL5 function in 
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hippocampal glutamatergic neurons plays a key role in mechanisms of learning and 
memory.   
Finally, two conditional KO mouse models of CDD were recently generated to 
investigate the effects of loss of function of CDKL5 in excitatory cortical neurons (CDKL5 
Fl/Y CaMKIIα-cre mice) and in inhibitory neurons (CDKL5 Fl/Y +/− Gad2-IRES-Cre mice; 
Schroeder et al., 2018). No behavioral studies were conducted in these mice, however, 
loss of CDKL5 in excitatory and inhibitory neurons respectively was found to differentially 
dysregulate components of mTOR signaling (Schroeder et al., 2018), a critical pathway 
that integrates intracellular and extracellular cues to modulate gene expression, protein 
synthesis and neuronal growth (Lipton and Sahin, 2014). Further investigation must be 
performed to investigate the consequence of such disruption in terms of downstream 
alterations in cell signaling or metabolic pathways.  
The Cdkl5R59X model 
The Cdkl5R59X (R59X) mouse was developed in the laboratory of Dr. Zhaolan Zhou at the 
University of Pennsylvania based on a mutation found in a human patient with CDD 
known to have severe daily seizures that began shortly after birth (Castrén et al., 2011). 
Tonic flexion of her upper limbs was associated with sharp-wave discharges in EEG 
recordings and her seizures were only just controlled by multiple anti-epileptic drugs 
including valproic acid, oxcarbazepine, and vigabatrin. By six years of age, the patient 
exhibited severe intellectual disability, stereotyped behaviors and poor eye contact 
(Castrén et al., 2011). R59X mice are on a C57BL/6J genetic background and were 
produced with a targeting vector that was designed to insert a frt-flanked neomycin 
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resistance (neo) cassette downstream of exon 5 and a single nucleotide change of C to 
T, leading to a nonsense mutation at arginine 59 (R59X) of the cyclin-dependent kinase-
like 5 (CDKL5) gene. To date no studies have been published evaluating behavioral, 
molecular, or functional alterations in R59X mice.  
II. Excitatory:inhibitory (E:I) balance in development and disease 
Synapses mediate excitatory and inhibitory neurotransmission in the brain, and synaptic 
activity modulates essential processes of normal neuronal function such as intracellular 
signaling, gene regulation, protein trafficking, and plasticity (Citri and Malenka, 2008; 
Okuno, 2011; Kaushik et al., 2014). Furthermore, synaptic activity is dynamically 
regulated during development through differential expression of neurotransmitter 
receptor subunits to facilitate a period of heightened experience-dependent synaptic 
plasticity (Rakhade and Jensen, 2009). It is therefore unsurprising that synaptic 
dysfunction underlies neurodevelopmental disorders such as autism, intellectual 
disability, and epilepsy, and is a convergence point of disease pathogenesis (Zoghbi and 
Bear, 2012; Keller et al, 2017). 
Developmental regulation of neurotransmitter receptors  
Glutamate and GABA are the main neurotransmitters in the brain and mediate excitatory 
and inhibitory neurotransmission respectively (Ben-Ari, 2002; Owens and Kriegstein, 
2002; Willard and Koochekpour, 2013). When released from vesicles at the presynaptic 
membrane they travel across the synaptic cleft and bind glutamate or GABA receptors at 
the post-synaptic membrane. Neurotransmitter binding to ionotropic glutamate or GABA 
receptors induces a conformational change in the receptors, opening an ion channel 
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pore that allows the flow of small anions or cations (Owens and Kriegstein, 2002; Willard 
and Koochekpour, 2013). Glutamate binding causes positively charged sodium and 
calcium ions to enter the synapse, causing depolarization that can result in an action 
potential. In the adult brain, neurons become hyperpolarized and less likely to fire an 
action potential after GABA binding due to influx of negatively charged chloride ions. 
However, in the immature brain the chloride gradient at GABAA receptors is reversed 
due to the developmental regulation of chloride channels NKCC1 and KCC2. This 
causes GABA to be excitatory during early developmental periods, contributing to 
hyperexcitability and increased susceptibility to seizures (Ben-Ari, 2002).  
Ionotropic glutamate receptors are tetrameric structures responsible for fast synaptic 
transmission in the brain. The predominant ionotropic glutamate receptors are N-methyl-
D-aspartate receptors (NMDARs), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptors (AMPARs), and kainate receptors (Willard and Koochekpour, 2013). 
Changes in NMDAR and AMPAR levels are commonly associated with neurological 
deficits such as seizures, autism, and intellectual disability (Rakhade and Jensen, 2009; 
Rojas, 2014).   
NMDARs are composed of two obligate GluN1 subunits along with two GluN2 subunits 
or GluN3 subunits, of which there are GluN2A, GluN2B, GluN2C, GluN2D, GluN3A and 
GluN3B subtypes  (Paoletti et al., 2013). In the adult brain GluN2A and GluN2B are 
predominantly expressed  (Watanabe et al., 1992) and play a significant role in synaptic 
function and plasticity (Paoletti et al., 2013). In the immature brain however, GluN2B, 
GluN2D, and GluN3A are all highly expressed to contribute to elevated excitability. All 
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NMDARs are permeable to Ca2+ and are sensitive to a voltage-dependent Mg2+ block, 
but subunit composition modulates receptor deactivation kinetics or sensitivity to Mg2+. 
For example, during development, high levels of GluN2B extend the current decay 
times, and GluN2D and GluN3A decrease sensitivity to the magnesium block. 
Additionally, there are more total NMDARs present during early development, 
contributing to increased Ca2+ influx. These NMDAR receptor changes facilitate a period 
of rapid synapse formation and circuit development, but they also cause the brain to be 
more susceptible to seizures (Rakhade and Jensen, 2009).  
AMPARs are composed of GluA1, GluA2, GluA3, GluA4 and are predominantly found in 
combinations of GluA1/2 or GluA2/3 at adulthood  (Wenthold et al., 1996; Mansour et al., 
2001), although GluA2-lacking AMPARs do exist and are present particularly during 
early-postnatal development  (Monyer et al., 1991). AMPARs, unlike NMDARs, are 
predominantly impermeable to Ca2+ due to inclusion of the GluA2 subunit. GluA2 mRNA 
undergoes post-transcriptional editing that changes a glutamine residue in the channel 
pore to arginine. The positively charged arginine residue prevents both the passage of 
Ca2+ ions and block by endogenous intracellular polyamines at high voltages, and also 
reduces single channel conductance (Verdoorn et al., 1991; Jonas et al., 1994; Jonas 
and Neuron, 1995; Swanson et al., 1997). Thus, GluA2-lacking AMPARs are Ca2+-
permeable and they also exhibit inward rectification in the AMPAR current-voltage plot 
due to the intracellular spermine block (Burnashev et al., 1992). Ca2+ not only 
contributes to neuronal excitation, but also is a critical secondary intracellular 
messenger, so even small changes in the levels of GluA2-lacking AMPARs can have 
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profound and long-lasting effects on excitability, plasticity, and intracellular signaling 
(Isaac et al., 2007).  
The role of GluA2-lacking AMPARs in synaptic development and function 
During development, GluA2-lacking AMPARs are upregulated to facilitate a period of 
activity-dependent synaptic plasticity  (Kumar et al., 2002; Pandey et al., 2015), but they 
are also present in high levels at adulthood in cortical GABAergic interneuron subtypes 
(Jonas et al., 1994) and are important at glutamatergic synapses for mechanisms of 
synaptic plasticity (Plant et al., 2006; Isaac et al., 2007; Sanderson et al., 2016). 
Transient incorporation of GluA2-lacking AMPARs at the synapse is necessary for 
NMDAR-dependent long-term depression (LTD), and blocking GluA2-lacking AMPARs 
impaired expression of LTD (Sanderson et al., 2016). Similarly, GluA2-lacking AMPARs 
are recruited to the synapse during the induction phase of long-term potentiation (LTP), 
before being removed and replaced by GluA2-containing AMPARs during the 
consolidation phase (Plant et al., 2006). Another study shows that GluA2-lacking 
AMPARs are delivered to peri-synaptic sites before expression of LTP  (Yang et al., 
2008), and that GluA2-lacking AMPARs are essential for LTP and enable activity-
dependent synaptic enlargement  (Yang et al., 2010). Interestingly, it appears that the 
anchoring and regulatory proteins that interact with GluA2-lacking AMPARs to the 
synapse play a large role in which form of plasticity is expressed (Guire et al., 2008; 
Park et al., 2016; Sanderson et al., 2016). Nevertheless, recruitment of GluA2-lacking 
AMPARs to the synapse is essential for several forms of plasticity, and disruptions in the 
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GluA2 subunit can have profound effects on synaptic scaling and plasticity throughout 
the lifetime.  
GluA2-lacking AMPARs in epilepsy, autism, and ID 
GluA2-lacking AMPARs are unique in that they are the only AMPAR subtype to allow 
Ca2+ influx. As a result, changes in GluA2 subunit levels can contribute to disease 
pathogenesis due to significant effects on synaptic scaling (Man, 2011), plasticity (Jia et 
al., 1996; Rakhade et al., 2008; Lippman-Bell et al., 2016), and downstream signaling 
pathways (Rosenberg et al., 2018). Dysregulation in GluA2-lacking AMPARs and 
associated regulatory proteins have been increasingly observed in several 
neurodevelopmental disorders. Decreased GluA2 is observed in neural progenitor cells 
from patients with Fragile X Syndrome, and results in increased Ca2+ influx and inward 
rectification in the current-voltage plot (Achuta et al., 2018). Downregulation of the 
intellectual disability protein RAB39B in hippocampal neurons causes synaptic GluA2 
deficits due to disrupted trafficking of the GluA2 subunit (Mignogna et al., 2015). Finally, 
the Jensen lab has observed that early-life hypoxic seizures (HS) cause GluA2 
dysregulation 48 hours post-HS (Lippman-Bell et al., 2016) and premature “unsilencing” 
of NMDAR-only synapses (Sun et al., 2018). GluA2 dysregulation post-HS results in 
immediate downstream mTOR pathway upregulation and MeCP2 phosphorylation 
(Talos et al., 2012; Rosenberg et al., 2018), and later-life autistic-like behavioral deficits 
and long-term epilepsy (Talos et al., 2012; Lippman-Bell et al., 2013). The Jensen lab 
also showed that blocking AMPARs immediately post-HS prevented the immediate 
mTOR upregulation (Talos et al., 2012) as well as later-life alterations in autistic-like 
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social deficits (Lippman-Bell., 2013), and occlusion of long-term plasticity (Zhou et al., 
2011), suggesting that blocking CP-AMPARs may have significant long-term therapeutic 
effects in epilepsy and autism.  
III. Novel therapeutic strategies for treatment-resistant early-life epilepsy 
The neonatal brain presents numerous challenges for therapeutics in part due to the 
differential expression of receptors that mediate the E:I balance (Rakhade et al., 2012). 
Traditional anti-epileptic drugs typically target the inhibitory system by increasing GABA 
activity or excitatory system by blocking glutamate receptors, sodium channels, voltage 
gated calcium channels, and potassium channels (Lee, 2014). Newer anti-epileptic 
drugs on the whole do not show increasing levels of efficacy compared to older 
treatments, supporting the need for novel therapeutics with varying mechanisms of 
action. We centered our therapeutic investigation in CDD on a GluA2-lacking AMPAR 
blocker and the experimental therapeutic cannabidiol.  
Therapeutic potential of GluA2-lacking AMPAR blockers 
AMPAR antagonists have strong anti-seizure activity in preclinical models of epilepsy, 
and recently the general noncompetitive AMPAR antagonist perampanel was the first 
AMPAR blocker approved for epilepsy in patients over 12 years of age [cite]. However, 
to date no GluA2-lacking AMPAR blockers have been implemented in either children or 
adults with epilepsy. IEM-1460 is a GluA2-lacking open channel blocker that has shown 
efficacy in delaying onset of PTZ-induced seizures immature rats (Szczurowska et al., 
2014). Furthermore, our lab has found that IEM-1460 treatment prevents downstream 
signaling alterations due to increased GluA2-lacking AMPARs after hypoxic seizures 
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(Rosenberg et al., 2018). Given the already increased population of GluA2-lacking 
AMPARs early in development, selectively blocking these receptors in patients with 
early-life epilepsy where the ratio of GluA2 to other subunits is even lower may show 
efficacy in seizure reduction or severity. In a recent study in Asian pediatric neurology 
clinics, perampanel was effective in reducing seizure frequency and was in general well-
tolerated as an add-on treatment for children and adolescents with epilepsy  (Lin et al., 
2018). However, there are currently no FDA approved drugs that selectively target 
GluA2-lacking AMPARs.  
Cannabidiol for use in treatment-resistant epilepsy   
Cannabidiol (CBD) is a cannabis-derived compound increasingly being used in 
treatment-resistant early-life epilepsies. CBD is the major non-psychoactive component 
of cannabis and recently has shown numerous anti-excitatory and immunomodulatory 
effects (Pisanti et al., 2017), and is reported to act at a multitude of cellular targets. 
Relevant to its anti-excitatory effects, CBD has poor activity at the endogenous 
cannabinoid receptors CB1 and CB2, but may indirectly affect the endocannabinoid 
system through its effects on other targets. CBD appears to block G-protein coupled 
receptor 55 (GPR55), a protein involved in regulating intracellular Ca2+  (Lauckner et al., 
2008). It also has activity activating transient receptor potential of vanilloid type-1 
(TRPV1; Bisogno et al., 2001), blocking T-type Ca2+ channels (Ross et al., 2008), and 
can target mutant sodium channels (Patel et al., 2016) Additionally, it has the ability to 
modulate adenosine receptors, voltage-dependent anion selective channel protein 
(VDAC1), and tumor necrosis factor alpha (TNFa) release (Devinsky et al., 2014).  
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CBD has exhibited anti-seizure properties in preclinical models of epilepsy (Do Val-da 
Silva et al., 2017; Kaplan et al., 2017), and rising off-label use of CBD in children with 
drug-resistant epilepsy recently led to the first double-blind placebo controlled clinical 
trials for CBD (commercial name Epidiolex) in several early-life epilepsies, including 
CDD, where it significantly reduced seizure frequency (Devinsky et al., 2018a, 2018b). 
Interestingly, CBD has also been reported by parents and some medical practitioners to 
have beneficial effects on autistic-like behaviors in children (Rosenberg et al., 2017). 
CBD treatment does attenuate social interaction deficits in a mouse model of Dravet 
syndrome, and prevents development of social recognition memory deficits in a 
transgenic mouse model of Alzheimer’s disease (Cheng 2014). However, further 
investigation is necessary to validate and expand upon these results.   
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CHAPTER 2 – Behavioral phenotyping of CDKL5 R59X mice  
Introduction 
Mouse models of neurodevelopmental disorders are an excellent method of investigating 
circuit and regional alterations in the brain, and many display characteristics at the whole 
animal level that are parallel to symptoms found in human patients. For example, Fmr1 
KO mice, a model of Fragile X Syndrome (FXS), displays increased seizure 
susceptibility to audiogenic seizures and also has been shown to exhibit elevated 
anxiety, autistic-like social deficits, and impairments in learning and memory (Musumeci 
et al., 2007; Kazdoba et al., 2014). The MeCP2 KO mouse, a model of Rett Syndrome 
(RTT), has similarly shown behavioral impairments that mirror characteristics of the 
human disease (Guy et al., 2001; Moretti et al., 2005). Although it is clearly not possible 
to perfectly replicate a complex neurodevelopmental human disorder in a mouse, these 
models have been valuable in furthering understanding of disease pathophysiology and 
in testing pharmacological interventions both at the circuit and whole animal levels. We 
chose to examine behavioral phenotypes in a novel mouse model of CDKL5 Deficiency 
Disorder (CDD), the CDKL5R59X mouse (R59X), to validate it as a relevant model to 
investigate potential molecular and functional alterations in CDD.   
Behavioral tests assessing home-cage activity, motor coordination and function, 
repetitive behaviors, sociability, and learning and memory are typically utilized to study 
mouse models of autism and other neurodevelopmental disorders. Here we chose to 
test R59X mice in a battery of behavioral assays that were of high relevance to 
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behaviors observed in patients with CDKL5 Deficiency Disorder (CDD), such as motor 
dysfunction, low sociability, and cognitive impairment.  
Hyperactivity and motor function deficits are often observed in cases of autism and 
intellectual disability  (Zingerevich et al., 2009; McClain et al., 2017), and in mouse 
models are typically assessed by the open field and rotarod assays. In the open field 
test, mice are placed in a home-cage like environment and allowed to roam freely to 
assess habituation and activity levels. The amount of time spent in the periphery vs the 
center of the arena is used as measure of anxiety-like behavior (Siebenhener 2015). 
Indeed, the amygdala, a brain region involved in anxiety-related behavior, is reported to 
be involved in open field activity along with the hippocampus  (Daenen et al., 2001). The 
rotarod performance test, in contrast, measures motor coordination and motor learning, 
and is mainly related to cerebellar function (Goodlett et al., 1991). Mice are placed on an 
accelerating rotarod and latency to fall off the rod is measured over 3 trials per day for 4 
days. Motor learning is assessed by how well mice learn to stay on the rod over 
repeated trials whereas latency to fall is a measure of motor coordination. Hyperactivity 
and impaired motor coordination in the open field and rotarod assays have been 
observed in several mouse models of autism  (Paylor et al., 1999; Kazdoba et al., 2014).  
Impaired sociability is another hallmark feature of autism, and can be investigated in 
mice using the three-chambered social choice test. Mice are placed into a three-
chambered arena with a social cue (a novel mouse) and non-social cue (inanimate 
object) in either end chamber. Time spent sniffing and investigating each cue is 
measured; mice will normally spend significantly more time investigating the novel 
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mouse than the object. Mouse models of neurodevelopmental disorders on the other 
hand, consistently exhibit decreased social interaction (Moretti et al., 2005; Kazdoba et 
al., 2014), which is thought to be mainly hypothalamus and amygdala-dependent  
(Young, 2002) although the hippocampus may also be involved in discriminating social 
and non-social stimuli (Raam et al., 2017).  
The Y maze and context-dependent fear conditioning paradigm are often utilized to test 
short and long-term hippocampal-dependent learning and memory respectively. For 
short-term memory, mice are placed in a Y shaped maze and allowed to explore the 
arms freely. Mice are naturally exploratory and normally will alternate the arms they 
explore so that spontaneous alternation behavior (SAB) is typically around 60%. 
However, mice with impaired short-term memory repeatedly enter the same arms 
causing SAB to be less than 50%. Long-term memory is assessed with the context-
dependent fear conditioning paradigm, which measures how well mice remember a foot 
shock after 24 hrs. Mouse models of FXS and RTT display significantly impaired fear 
memory (Stearns et al., 2007; Kazdoba et al., 2014) 
Although several mouse models of CDD have been developed that reflect core features 
of the human disease, including decreased motor coordination, social interaction deficits, 
and impaired learning and memory  (Tang et al., 2017; Wang et al., 2012; Amendola et 
al., 2014; Fuchs et al., 2015; Okuda et al., 2017, 2018), no mouse model to date has 
exhibited visible spontaneous seizures or abnormal EEG patterns. Furthermore, 
provocation of seizures using kainic acid does not reveal a difference in latency to 
epileptiform activity bursts (Amendola et al., 2014) or seizure severity (Okuda et al., 
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2017) in CDKL5 KO mice, though CDKL5 KO mice exposed to NMDA have increased 
seizure severity compared to WT littermates (Okuda et al., 2017). These data suggest 
that loss of CDKL5 does cause subtle hyperexcitability phenotypes in mice, but the 
variability between studies highlights the need for further investigation of seizure 
susceptibility in mouse models of CDD.  
The CDKL5R59X mouse is a novel model of CDD, developed after a mutation found in a 
human patient with severe seizures. The R59X mutation causes truncation of the kinase 
and a complete functional knock-out of the CDKL5 protein, which is comparable to 
constitutive knock-out models. However, demonstrating replicability and robustness of 
behavioral phenotypes and molecular alterations between mouse models is beneficial to 
our understanding of disease pathology. 
Results 
We show that whole brain lysates from R59X mice do not contain CDKL5 protein. Our 
behavioral analysis indicates that R59X mice display increased locomotion, social 
interaction deficits, and impaired working and long term memory. Additionally, they 
exhibit decreased latency to seizure behavior after a single low dose of 
pentylenetetrazol, suggesting that the mice have underlying hyperexcitability. These 
results verify that the R59X mouse is a relevant model to study the effects of loss of 
function of CDKL5 as well as investigate preclinical efficacy for potential therapeutics in 
CDD.  
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R59X mice do not express CDKL5 protein 
We used male R59X mice for all of our studies to avoid the confounding effects of X 
inactivation. To produce R59X mice, a targeting vector was designed to insert a frt-
flanked neomycin resistance (neo) cassette downstream of exon 5 and a single 
nucleotide change of C to T, leading to a nonsense mutation at arginine 59 (R59X) of the 
cyclin-dependent kinase-like 5 (CDKL5) gene. The construct was electroporated into 
C57BL/6N embryonic stem (ES) cells. Correctly targeted ES cells were injected into 
BALB/c blastocysts and resulting chimeric mice were bred with B6.Cg-
Tg(ACTFLPe)9205Dym/J to remove the neo cassette. Resulting offspring were bred to 
C57BL/6J mice for at least 10 generations to establish a colony of R59X mice. To 
confirm that CDKL5 is not present in the brain of R59X mice, whole-brain lysates from 
R59X mice and WT littermates were probed for CDKL5. No CDKL5 is present in the 
R59X brain (Fig. 2-1). 
R59X mice demonstrate hyperactivity and deficits in motor function 
We aimed to determine whether R59X mice exhibited alterations in activity and motor 
coordination because hyperactivity and motor deficits are frequently observed in patients 
with ASD and in ASD murine models  (Crawley, 2004, 2007; Brodkin, 2007; Moy et al., 
2008; Wang et al., 2012). In the open field assay, R59X mice exhibited greater motor 
activity by increased number of beam breaks over time compared to WT controls (Fig. 2-
2a. Two-way ANOVA, F9, 280= 15.86, interaction p<0.0001). Additionally, mutant mice 
spent more time in the periphery of the arena (Fig. 2-2b. Unpaired t test, R59X: 69.04 ± 
2.307 vs WT: 58.72 ± 2.900, p=0.0095), suggesting an elevated anxiety-like phenotype. 
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In the rotarod assay, R59X mice displayed decreased latency to fall, demonstrating 
impaired motor coordination (Fig. 2-2c. Two-way ANOVA, F1, 336 = 30.13, main effect of 
genotype p<0.0001). Despite this impairment, latency to fall in mutant mice increased 
similarly across trials to WT, suggesting that the rate of motor learning was not altered. 
Finally, R59X mice had a significantly greater hindlimb clasping score than littermate 
controls (Fig. 2-2d. Unpaired t test, R59X: 2.200 ± 0.1447 vs WT: 0.6667 ± 0.1869, 
p<0.0001), a phenotype observed in other mouse models of autism and CDD that is 
interpreted as impaired motor function  (Guy et al., 2001; Wang et al., 2012). These data 
show that R59X mice are hyperactive and have motor coordination and function deficits, 
phenotypes commonly observed in autism (Dewey et al., 2007).  
R59X mice exhibit social interaction deficits  
We next investigated sociability in R59X mice in the three-chambered social approach 
test, given the hallmark social interaction deficits in CDD and ASD (Bahi-Buisson et al., 
2008b; Fehr et al., 2015). As expected, neither WT nor R59X mice showed a chamber 
preference during the initial habituation phase. However, upon introduction of a novel 
mouse, R59X mice spent significantly less time interacting with the novel mouse 
compared to WT littermates (Fig. 2-2e. Two-way ANOVA, F1, 47= 115.6, interaction 
p<0.0001, Sidak’s multiple comparisons test R59X: 16.653 ± 2.536 vs WT: 61.903 ± 
3.3737, p<0.0001). Furthermore, during the five-minute direct interaction period R59X 
mice spent significantly less time sniffing and interacting with the novel mouse than WT 
littermates (Fig. 2-2f. Unpaired t test, R59X: 26.43 ± 5.493 vs WT: 64.85 ± 5.002, 
p<0.0001). The deficit in social interaction in R59X mice was not due to impaired 
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olfactory function, given there were no differences in time spent sniffing neutral, vanilla, 
and social scents between mutant mice and controls in the olfactory test (Fig. 2-2g).  
R59X mice have learning and memory impairments 
We tested whether R59X mice also have deficits in working and long-term memory, 
given that intellectual disability is another core feature of CDD  (Fehr et al., 2016). The Y 
maze assay was used to test hippocampal-dependent working memory  (Murray and 
Ridley, 1999), where mice were allowed to freely explore a maze with three arms. The 
number of alternation events was measured, where one alternation event was when the 
mouse entered all three arms without repeating one. We found that R59X mice had 
significantly decreased percent spontaneous alternation behavior (% SAB) compared to 
WT littermates, indicating a deficit in working memory (Fig. 2-2h. Unpaired t test, R59X: 
44.03 ± 2.061 vs WT: 57.49 ± 1.329, p<0.0001). We then performed context-dependent 
fear conditioning to examine potential changes in hippocampal-dependent long-term 
memory  (Phillips and LeDoux, 1992). Fear conditioning was performed over two days, a 
training day (day 1) and testing day (day 2). On day 1, both R59X mice and WT 
littermates showed similar levels of exploratory behavior during the habituation phase as 
well as comparable levels of freezing after the foot shock in the acquisition phase, 
indicating similar sensitivity to the foot shock. However, when placed back inside the 
shock-box 24 hours later (day 2) to test for long-term fear memory the R59X mice froze 
significantly less than WT littermates (Fig. 2-2i. Two-way ANOVA, F2, 84 = 3.624, 
interaction p<0.0309, Sidak’s multiple comparisons test, R59X: 40.05 ± 4.865 vs WT 
61.936 ± 4.114, p<0.001). Taken together, these data demonstrate impaired 
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hippocampal-dependent short- and long-term memory in the R59X mice compared to 
WT littermates. 
R59X mice show decreased latency to seizure activity following administration of 
the chemoconvulsant pentylenetetrazol 
Epilepsy has high prevalence in CDD patients, and many patients are refractory to 
conventional anti-epileptic drugs (Bahi-Buisson et al., 2008). There were no observed 
spontaneous seizures during both behavioral testing and routine animal husbandry 
interactions with R59X mice, consistent with other CDD mouse models to date (Wang et 
al., 2012; Amendola et al., 2014; Okuda et al., 2017; et al., 2017).  Given the lack of 
evidence of a severe spontaneous seizure phenotype, we next aimed to determine 
whether R59X mice had elevated network hyperexcitability by evaluating seizure 
susceptibility. We therefore tested sensitivity to a single dose of pentylenetetrazol (PTZ, 
40 mg/kg), a GABAA antagonist  (Squires et al., 1984), which is well tolerated and 
causes mild seizure phenotypes (Racine stages 1-3) in WT mice. Mice were videotaped 
for 2 hours following PTZ administration and videos were scored for latency to onset of 
seizure activity. R59X mice exhibited significantly decreased latency to Racine stage 1 
compared to WT mice (Fig. 2-1j. Unpaired t test, R59X: 79.00 ± 6.869 vs WT: 123.9 ± 
14.46, p=0.0117). Seizure activity lasted on average 30 min post-injection for both R59X 
and WT mice, and no significant changes were found in total duration or overall severity 
of seizures (data not shown). Increased sensitivity to a sub-convulsive dose of PTZ 
suggests that although R59X mice do not exhibit spontaneous seizures, they do possess 
underlying hyperexcitability that may be contributing to their behavioral alterations.  
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Discussion 
We show that the novel R59X mouse model displays reproducible, autistic-like behaviors 
and hyperexcitability that are core to the disease. Based on the lab’s prior work 
(Lippman-Bell et al., 2013), this is plausible evidence for contributing molecular 
alterations that may be novel therapeutic targets in CDD. R59X mice display 
hyperlocomotion, decreased motor coordination, social interaction deficits, and 
impairments in spatial working memory as well as long-term hippocampal-dependent 
fear memory. Furthermore, R59X mice display decreased latency to seizure, indicating 
underlying hyperexcitability even in the absence of visible spontaneous seizures. Our 
results show that R59X mice replicate core clinical features of CDD. Importantly, R59X 
mice displayed increased susceptibility to seizure upon administration of a sub-
convulsive dose of PTZ, indicating subtle hyperexcitability in the brain. This novel finding 
has not been observed in other mouse models of CDD. While spontaneous seizures or 
abnormal EEGs have not been observed in any rodent model of CDD to date  (Wang et 
al., 2012; Amendola et al., 2014; Okuda et al., 2017), increased seizure severity has 
recently been shown in CDKL5 KO mice in response to NMDA, although the sample size 
in the study was quite small (Okuda et al., 2017). The same study reported that kainic 
acid had no effect on seizure score, although a prior report indicated that kainic acid 
decreased the total number of seizure events in CDKL5 KO mice but had no effect on 
latency or duration (Amendola et al., 2014). The variations in observed results may be 
due to the distinct pharmacology and doses of chemoconvulsants used, ages of mice at 
testing, and other environmental factors such as stress.  
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Increased seizure susceptibility is an indicator of altered excitatory:inhibitory (E:I) 
balance, which is mediated by excitatory and inhibitory receptors as well as ion 
transporters that regulate the electrochemical gradient in the brain (Eichler and Meier, 
2008). In particular, excitatory glutamate receptor dysregulation is often observed in both 
autism and early-life epilepsy (Rakhade et al., 2012; Barker-Haliski and White, 2015; 
Fung and Hardan, 2015;  Lippman-Bell et al., 2013, 2016) and will be discussed in the 
context of R59X mice in the next chapter. 
The results shown here are similar to studies performed in constitutive knock-out mouse 
models of CDD where mutant mice exhibited hyperlocomotion (Wang et al., 2012; 
Okuda et al., 2018), decreased motor coordination (Wang et al., 2012), social interaction 
deficits  (Wang et al., 2012; Jhang et al., 2017; Okuda et al., 2018), and impaired 
working and long-term context-dependent fear memory  (Wang et al., 2012; Fuchs et al., 
2015; Okuda et al., 2018). The robust replicability of deficits in social behavior and 
learning and memory across multiple mouse models of CDD highlight that normal 
function of CDKL5 is critical for these processes. 
The hippocampal-associated memory deficits observed in R59X mice suggest that 
CDKL5 is important for normal hippocampal function. Indeed, impairments in 
hippocampal short-term working memory and long-term contextual fear memory have 
been observed in several constitutive knock-out mouse models of CDD (Wang et al., 
2012; Fuchs et al., 2015; Okuda et al., 2018). Furthermore, these memory deficits were 
also observed in a conditional knock-out mouse where CDKL5 was deleted from 
glutamatergic neurons in cortex and hippocampus (Tang et al., 2017), suggesting that 
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not only is CDKL5 critical for hippocampal function, but that it likely plays a significant 
role in excitatory neurons allowing for normal processes that contribute to learning and 
memory.  
Although several behaviors observed in R59X mice have been observed previously in 
CDKL5 KO mice (Wang et al., 2012), phenotyping this novel model is nonetheless 
valuable in showing robustness and replicability of the effects of loss of function of 
CDKL5. Furthermore, we verify that loss of CDKL5 in mice does cause subtle 
hyperexcitability in the absence of visible spontaneous seizures.  
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Materials and Methods 
Animals 
All procedures were performed in accordance with the guidelines of the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and approval of 
Institution of Animal Care and Use Committee at the University of Pennsylvania 
(Philadelphia, PA). All studies were performed on R59X mice and age-matched WT 
littermates on a congenic sv129:C57BL/6 background, available at Jackson Labs, stock 
number 028856. Mice were originally produced in the laboratory of Dr. Zhaolan Zhou at 
the University of Pennsylvania. To produce R59X mice, a targeting vector was designed 
to insert a frt-flanked neomycin resistance (neo) cassette downstream of exon 5, and a 
single nucleotide change of C to T, leading to a nonsense mutation at arginine 59 
(R59X) of the Cdkl5 gene. The construct was electroporated into C57BL/6N embryonic 
stem (ES) cells. Correctly targeted ES cells were injected into BALB/c blastocysts and 
resulting chimeric mice were bred with B6.Cg-Tg(ACTFLPe)9205Dym/J to remove the 
neo cassette. Resulting offspring were bred to C57BL/6J mice for at least 10 generations 
to establish a colony of R59X mice. 
Male mice were used for all experiments to avoid confounding effects of X-inactivation 
that would be present in heterozygous female mice. All efforts were made to minimize 
animal suffering and numbers. Mice were genotyped using a PCR protocol designed to 
detect the R59X mutation. The genotyping primers (5’-
GCTGCTTACATTAGGAGAGACTGC-3’ and 5’-GTCACATGACCAGCCAGCGT-3’) give 
rise to a 204 bp product from WT mice and a 347 bp product from the knock-in mutation.  
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Western blotting 
Brains from P7, P14, P21, P30, P50, and P125 R59X mice and WT littermates were 
rapidly dissected from the skull. Tissue was flash-frozen in chilled ethanol and stored at 
-80°C until homogenization. Whole cell protein extraction was performed as described 
previously (Wenthold et al., 1992; Talos et al., 2006; Rakhade et al., 2012). Halt 
Protease and Phosphatase Inhibitor Cocktail EDTA-free (Thermo Fisher) and PMSF 
(Thermo Fisher) were added to inhibit proteases and phosphatases. Total protein 
concentrations were measured by the Bradford protein assay (Bio-Rad) and samples 
were diluted to obtain equal amounts of protein for each sample (1µg/ul). Samples were 
separated by gel electrophoresis on Criterion TGX 4-20% precast gels and transferred to 
PVDF membranes (Immobilon-FL). Primary antibodies used in this study were CDKL5 
(1:1000; Millipore; MABS1132) and β-actin (1:3000; Sigma; A5441). Secondary 
antibodies used were rabbit IRDye 800CW and mouse IRDye 680LT (Licor). The 
Odyssey Infrared Imaging System protocols were used for blots and quantification of 
protein expression 
Animal Behavior  
All behavioral studies were performed blinded to genotype. Mice were allowed habituate 
in the testing room at least 30 minutes before each test. All tests were performed at the 
same time of day. Behavioral tests were performed on male R59X mice and WT 
littermates at 12-16 weeks of age.  
Open-field assay. Home cage-like activity was monitored by beam breaks in a 
photobeam frame. Mice were placed into a clean environment in a photobeam frame. 
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The number of beam breaks over 10 minutes was quantified as a measure of locomotor 
activity, with the first three minutes denoted as the habituation period.  
Y maze. Mice were placed at the end of one arm of a Y-shaped apparatus where each 
arm was labeled. Arm entries were recorded as they occurred. The mouse was 
considered to enter an arm when all four paws were in the arm. The mouse was allowed 
to explore the maze for 8 minutes. Percent spontaneous alternation behavior (% SAB) 
was calculated using the following formula: % SAB= [(number of alternations/total arm 
entries-2)] ×100.  
Three-chambered social approach test. The social approach assay was performed in a 
three-chambered arena consisting of a center chamber and two end chambers, as 
previously described  (Brodkin, 2007). One end chamber was designated the “social 
chamber” while the other was designated the “non-social” chamber. Two Plexiglas 
cylinders with air holes are placed in each end chamber. The test mouse is placed in the 
arena for a 10-minute habituation phase, during which the amount time spent in each 
chamber was measured (baseline). For the social phase, a stimulus mouse (adult 
gonadectomized A/J mouse; Jackson Labs) was placed in the cylinder in the social 
chamber, and a novel object was placed in the cylinder in the non-social chamber. The 
test mouse was again allowed to explore the arena for 10 minutes. Time spent in each 
chamber over the 10-minute test phase was measured.  
Context-dependent fear conditioning. In the training phase, mice were placed in 
conditioning chambers for 3 minutes terminated with a 1.5 mA foot shock. The 
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uniqueness of the chamber is considered as the conditioned stimulus. Mice were left in 
the chamber for 1 minute after the foot shock. Mice are returned to the conditioning 
chamber 24 hours later for a 5-minute test phase. Time spent freezing (no motion except 
for respiratory movements) during the 5-minute test phase is measured with Freezescan 
software by Clever Systems.  
Accelerating rotarod assay. Adapted from Rothwell et al, Cell 2014. A five station rotarod 
treadmill (IITC) was modified with a pulley and belt purchased from the vendor to 
increase the standard of acceleration, allowing the rotarod to attain speeds of up to 80 
rpm while maintaining a constant rate of acceleration over a 300 second trial. Mice were 
placed on the rotarod for 3 trials per day over 4 consecutive days with at least a 15-
minute inter-trial interval. On day 1 mice were allowed to acclimate to the stationary rod 
for 1 minute before beginning the first trial. Days 1 and 2 consisted of 4-40 rpm trials and 
days 3 and 4 consisted of 8-80 rpm trials. Trials were terminated after a mouse fell off 
the rod, made one complete revolution while clinging to the rod, or after 300 seconds 
(maximum speed).  
Hindlimb clasping test. Mice were picked up by the base of the tail and lifted clear of all 
surrounding objects. Hindlimb position was observed for 10 seconds. If the hindlimbs 
were consistently splayed outward, away from the abdomen, the mouse was assigned a 
score of 0. If one hindlimb was retracted towards the abdomen for more the 50% of the 
time, the score was 1. If both hindlimbs were partially retracted for greater than 50% of 
the time, the score was 2. Finally, if hindlimbs were entirely retracted and touching the 
abdomen for more than 50% of the time suspended, the mouse received a score of 3.   
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Olfactory test. Mice were tested to observe whether they could detect and differentiate 
odors. Mice were exposed to cotton-tipped wooden applicators dipped in water, vanilla, 
or swiped across the bottom of an unfamiliar social cage. Each applicator was presented 
for 2 minutes with a 1-minute interval between applicators. Time spent sniffing was 
defined as when the mouse had its nose within 2 cm of the cotton tip.  
PTZ seizure threshold test. 18-week-old male R59X mice and WT littermates were 
allowed to habituate in the procedure room for 30 minutes. Mice were injected with a 
sub-threshold dose of PTZ (40 mg/kg) and placed in a Plexiglas grid of 12 individual 
chambers. Each chamber had fresh bedding. Mice were video-monitored for 2 hours. 
Videos were scored by blinded observer using a modified Racine scale  (Lüttjohann et 
al., 2009); 0: normal behavior, 1: freezing or immobility for at least 5 seconds, 2: 
myoclonic jerks, 3: forelimb clonus, 4: rearing, forelimb clonus, 5: tonic-clonic, loss of 
posture. 
Experimental design and statistical analysis 
For behavioral tests, we chose sample sizes based on previously published results in 
the CDD literature. The number of mice used in each experiment was predetermined 
before the start of the experiment and based on prior behavioral work in CDKL5 KO 
mice (Wang et al., 2012). 
Stastical analysis was completed using GraphPad Prism. All datasets were analyzed 
using the D’Agostino–Pearson test for normality. Datasets with normal distributions were 
analyzed for significance using unpaired Student’s two-tailed t test. Two-way repeated-
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measures ANOVA was conducted for comparing mean differences between groups that 
have been split on two independent variables with Holm–Sidak’s multiple-comparison 
test. 
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Figures 
Figure 2-1 
 
Figure 2-1: Western blot showing absence of CDKL5 protein in R59X whole brain 
lysates. b-actin is the loading control.  
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Figure 2-2 
 
Figure 2-2: R59X mice display behavioral deficits consistent with mouse models 
of autism and intellectual disability, and lowered seizure threshold. a. Ten-minute 
open field locomotion test measuring number of infrared beam breaks over time. R59X 
mice exhibit increased activity compared to WT littermates, after a 3-minute habituation 
period. Two-way ANOVA, p<0.0001 (interaction). b. R59X spend significantly more time 
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in periphery of the open field arena, indicating elevated anxiety compared to WT. 
Unpaired t test, p=0.0095. c. Accelerating rotarod assay measuring latency to fall. R59X 
mice show comparable motor learning but decreased motor coordination compared to 
WT mice. Two-way ANOVA, p<0.0001 (main effect of genotype). d. Five second 
hindlimb clasping test assessing motor neuron function with a score of 0 representing no 
hindlimb clasping and a score of 4 representing both hindlimbs clasped in the middle 
during the entire trial period. R59X mice display increased clasping compared to WT 
littermates. Unpaired t test, p<0.0001. e. Three-chambered social choice assay 
measuring social interaction. WT and R59X mice spend comparable amounts of time 
sniffing the non-social object (NS), but R59X mice spend significantly less time sniffing 
the stimulus mouse (S). Two-way ANOVA with Sidak correction for multiple 
comparisons, p<0.0001 (interaction), p<0.0001. f. Five-minute direct interaction period 
with freely moving stimulus mouse. R59X mice spend less time interacting with stimulus 
mouse than WT littermates. Unpaired t test, p<0.0001. g. Olfactory test measuring time 
spent sniffing neutral, vanilla, and social scents. R59X mice and WT controls spend 
comparable amounts of time sniffing each scent. Two-way ANOVA, p=0.9499. h. Y 
maze assay testing working memory by measuring spontaneous alternation behavior (% 
SAB). R59X mice alternate arms of the Y maze significantly less than WT controls, 
suggesting impaired working memory. Unpaired t test, p<0.0001. i. Context-dependent 
fear conditioning assay measuring freezing behavior. R59X mice freeze similar amounts 
after a mild foot shock compared to WT mice (post-shock) but show decreased freezing 
upon returning to the testing chamber 24 hours later (context). Two-way ANOVA with 
Sidak correction for multiple comparisons, p=0.0309 (interaction). (N=15 for all groups in 
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a-i.) j. Seizure threshold test measuring latency to first behavioral seizure after PTZ 
injection. R59X (N=10) reach the first behavioral seizure significantly faster than WT 
littermates (N=10). Unpaired t test, p=0.0117. *p<0.05, **p<0.01, ****p<0.0001 
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CHAPTER 3 – Glutamate receptor and chloride channel analysis in 
R59X mice and two human cases of CDD 
Introduction 
Given the behavioral deficits and hyperexcitability observed in R59X mice, we 
hypothesized that mutant mice would exhibit underlying alterations in proteins involved 
in regulating the excitatory:inhibitory balance. Glutamate receptors, which include α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), N-methyl-D-
aspartate receptors (NMDAR) and kainate receptors, are heterotetrameric structures 
that mediate excitatory neurotransmission in the brain. NMDARs are composed of the 
obligate GluN1 subunit and a combination of two GluN2 or GluN3 subunits of which 
there are GluN2A-D, GluN3A, and GluN3B (Paoletti et al, 2013). AMPARs are are 
composed of GluA1-4 subunits (Greger et al., 2017). Expression and localization of 
receptor subunits are dynamically regulated throughout development by activity-
dependent, transcriptional, and translational mechanisms (Paoletti et al., 2013; Greger et 
al., 2017), and altering receptor composition and biophysical properties to regulate the 
excitatory-inhibitory (E-I) balance throughout the lifetime (Luján et al., 2005; Rakhade 
and Jensen, 2009). Dysregulated glutamate receptor subunit expression is often 
associated with epilepsy, autism, and ID  (Loddenkemper et al., 2014; Mignogna et al., 
2015; Lippman-Bell et al., 2016).  
Importantly, modest changes in the tightly regulated GluA2 AMPAR subunit can have a 
profound effect on excitability and signal transduction due to the distinct properties of 
GluA2  (Lippman-Bell et al., 2013; Uzunova et al., 2014; Stephenson et al., 2017). Most 
notably, GluA2-lacking AMPARs are Ca2+-permeable and play a significant role in 
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regulating dendritic spine enlargement as well as downstream signaling and gene 
transcription  (Plant et al., 2006; Isaac et al., 2007; Fortin et al., 2010; Henley and 
Wilkinson, 2016). Indeed, we have previously observed decreased GluA2 expression 
following neonatal hypoxic seizures in wild-type rats, which contributes to social 
interaction deficits, elevated activity-dependent Ca2+ influx, altered downstream 
signaling, and increased epileptogenesis  (Sanchez et al., 2001; Rakhade et al., 2008; 
Lippman-Bell et al., 2013, 2016; Rosenberg et al., 2018). Finally, altered GluA2 subunit 
expression has been observed in several neurodevelopmental disorders such as Rett 
syndrome, Fragile X syndrome, tuberous sclerosis, and RAB39B-associated mental 
retardation  (Talos et al., 2008; Mignogna et al., 2015; Li et al., 2016; Achuta et al., 
2018), pointing to a critical role of GluA2 in neurodevelopmental disease 
pathophysiology.  
Given that elevated GluA2-lacking AMPARs have been previously linked to 
neurobehavioral deficits and Cdkl5 knock-down causes dysregulated GluA2 in neurons 
in vitro  (Tramarin et al., 2018), we investigated levels of AMPAR subunits GluA1 and 
GluA2 in the novel R59X mouse model of CDD. However, we also included NMDAR 
subunits GluN2A and GluN2B, as well as chloride transporter NKCC1 and KCC2 in our 
protein analysis. NMDARs and chloride transporters also play a huge role during 
development in regulating the E:I balance  (Luján et al., 2005; Rakhade and Jensen, 
2009), and have been found to be dysregulated in epilepsy and various 
neurodevelopmental disorders such as Fragile X Syndrome and autism  (Dzhala et al., 
2005; Uzunova et al., 2014). Furthermore, glutamate receptors and chloride channels 
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can be activated and blocked by various pharmacological agents, making them attractive 
therapeutic targets in autism and epilepsy (Puskarjov et al., 2014; Barker-Haliski and 
White, 2015; Fung and Hardan, 2015).  
 
Results 
Decreased membrane-bound GluA2:GluA1 protein in R59X hippocampus 
Given that previous studies support a role for CDKL5 in stabilizing excitatory synaptic 
scaffolding proteins that are involved in anchoring of neurotransmitter receptors and 
regulatory proteins at the membrane (Ricciardi et al., 2012; Della Sala et al., 2016) , we 
hypothesized that R59X mice may have molecular and functional alterations in NMDAR 
or AMPAR subunits associated with the aforementioned behavioral deficits and seizure 
susceptibility. We performed Western blot analysis across a developmental range from 
early postnatal (P7) to adult (P50) in cortical and hippocampal membrane-prepped 
tissue of NMDAR subunits GluN2A and GluN2B, and AMPAR subunits GluA1 and 
GluA2, the predominant AMPAR subunits in the brain (Lu et al., 2009; Reimers et al., 
2011). Although levels of GluA1 in R59X mice were unaltered compared to WT 
littermates at all time points (Fig. 3-1a), R59X mice showed significant decreases in 
hippocampal membrane-bound GluA2 at P30 and P50 (Fig. 3-1b. Multiple t test, P30: 
p=0.0089; P50: p=0.0053). We wanted to see whether this decrease persisted 
throughout adulthood and extended our Western blot analysis in hippocampal tissue to 
P125. Indeed, decreased GluA2 was observed at this time point as well (Fig. 3-1b. 
Multiple t tests, P125: p=0.0193), indicating a persistent decrease of membrane-bound 
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GluA2 in the hippocampus. Importantly, when considering the ratio of subunits 
GluA2:GluA1, which is a measure of GluA2-lacking AMPARs, R59X mice had 
significantly decreased GluA2:GluA1 in the hippocampus at P30, P50, and P125 (Fig. 3-
1c. Multiple t tests, P30: p=0.0180; P50: p=0.0002; P125: p=0.0048), suggesting 
reduced GluA2-containing AMPARs, or in other words increased hippocampal GluA2-
lacking AMPARs. Decreased GluA2 was specific to the hippocampus; no significant 
changes in GluA1 and GluA2 expression were observed across the lifespan in the cortex 
of R59X mice (Fig. 3-1h-k). GluA2-lacking AMPARs are Ca2+-permeable and are key 
regulators of synaptic function and plasticity that are particularly implicated in 
neurodevelopmental disease pathophysiology (Isaac et al., 2007; Uzunova et al., 2014; 
Lippman-Bell et al., 2016; Rosenberg et al., 2018). Therefore, decreased GluA2:GluA1 
in R59X hippocampus may contribute to hyperexcitability and hippocampal-dependent 
learning and memory observed in the whole animal.  
Levels of NMDAR subunits and chloride transporters are not altered in the 
hippocampus or cortex in R59X mice  
Interestingly, no significant alterations were observed in membrane-bound GluN2A, 
GluN2B, and the ratio of GluN2B:GluN2A at any developmental time point in the 
hippocampus of R59X mice compared to controls (Fig. 3-2a-c), contrary to a recent 
study showing elevated GluN2B at CA1 synapses in CDKL5 KO mice (Okuda et al., 
2017). There were no observed alterations in NMDAR subunits in R59X cortex (Fig. 3-
2e-g). We also investigated the levels of the developmentally regulated chloride 
channels NKCC1 and KCC2 which have been found to be dysregulated in Tuberous 
sclerosis (Talos et al., 2012). Levels of NKCC1 and KCC2 were not altered in either 
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hippocampus or cortex of R59X mice at any time point (Fig. 3-3a-g). These data suggest 
that neither NMDARs nor chloride transporters contribute to lowered seizure threshold or 
behavioral abnormalities in R59X mice.  
Fraction of synapses containing GluA2 is significantly decreased in CA1 and 
dentate gyrus hilus 
To determine whether the decreases in membrane-associated GluA2 was occurring at 
intact synapses, we performed immunohistochemistry of surface GluA2 or GluA1 
staining colocalized with presynaptic marker synapsin. The fraction of synapsin puncta 
that colocalized with surface GluA2 was calculated using the Manders coefficient 
(Manders et al., 1993). The Manders coefficient has previously been used to quantify 
association of GABAA subunits with inhibitory synaptic anchoring protein gephyrin (Gao 
and Heldt, 2016). We found that the fraction of synapses containing GluA2 was 
significantly decreased in R59X CA1 s. radiatum (Fig. 3-4a,b. Multiple t tests, p<0.05) 
whereas the fraction of CA1 synapses containing GluA1 was unaltered compared to WT 
littermates (Fig. 3-4c,d). Similarly, R59X dentate gyrus hilar neurons showed significantly 
less GluA2-containing synapses (Fig. 3-5a,b. Multiple t tests, p<0.01) while GluA1-
containing synapses were not altered (Fig. 3-5c,d). Interestingly, this pattern of 
decreased GluA2-containing synapses was not observed in CA3 s. radiatum (Fig. 3-
6a,b) and fraction of GluA1-containing synapses was not altered either (Fig. 3-6c,d). 
Finally, we investigated cortex layer II/III for alterations in GluA2 and GluA1-containing 
synapses. Although our Western blot analysis showed no change in the cortex for GluA2 
and GluA1, we were curious to see whether we could observe layer II/III-specific 
changes particularly because long-term potentiation (LTP) has been reported to be 
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decreased in layer II/III in CDKL5 KO mice (Della Sala et al., 2015) and GluA2-lacking 
AMPARs are involved with LTP induction (Plant et al., 2006). However, there were no 
alterations in GluA2- or GluA1-containing synapses in layer II/III in R59X mice (Fig. 3-7). 
Expression and whole cell levels of GluA1 and GluA2 are not altered in R59X 
hippocampus 
Prior reports suggest that CDKL5 shuttles from the cytoplasm to the nucleus where it 
may affect gene regulation (Rusconi et al., 2008), and the observed changes in GluA2 
protein expression may be secondary to transcriptional changes.  Therefore, we next 
used RT-qPCR to measure the relative mRNA transcript levels of Gria1 or Gria2 (for 
GluA1 and GluA2 respectively) in hippocampal tissue from P50 R59X mice and WT 
littermates.  We found that R59X mice do not have significantly altered mRNA transcript 
levels of Gria1 or Gria2 (Table 1). Furthermore, in whole cell hippocampal homogenates 
there were no changes in total protein levels of GluA1 or GluA2 in R59X mice compared 
to controls (Table 1). These data suggest that decreased membrane-bound GluA2 in the 
R59X hippocampus is more likely due to alterations in membrane trafficking or 
localization than altered expression of the subunits themselves.  
Investigation of GluA2 trafficking proteins in R59X hippocampus 
Given the decrease in membrane-associated GluA2 without a concomitant decrease in 
transcription or total protein levels, we next investigated whether altered post-
translational phosphorylation of GluA2 at Ser880 (GluA2S880), which normally causes 
internalization of GluA2, could be responsible for the observed differences. However, we 
observed no change in GluA2S880 in the R59X hippocampus (Table 1). We also did not 
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observe alterations in levels of PICK1, CaMKII, or RAB39B (Table 1), proteins that are 
involved in GluA2 trafficking from the endoplasmic reticulum to the membrane  (Lu et al., 
2014; Mignogna et al., 2015; Lorgen et al., 2017). However, trafficking of GluA2 may be 
dysregulated at numerous other pathways that we did not have the chance to 
investigate.  
Exploring human tissue to validate neurotransmitter receptor expression changes 
in postmortem hippocampal tissue from CDD patients  
We obtained postmortem brain tissue samples from two patients with CDD and sought 
to determine if a similar trend of decreased GluA2:GluA1 could be observed in the 
human hippocampus, adding some clinical relevance to the results we obtained in the 
R59X model. Indeed, although statistical analysis could not be performed with just two 
cases, we see a trend towards decreased GluA2:GluA1 in CDD hippocampus (Figure 3-
8a.). This is an intriguing finding given the varied ages of the cases (5 and 30 years old) 
and the likelihood that they were on different anti-epileptic drug regimens that could 
differentially affect levels of neurotransmitter receptors. The differences in NMDAR 
subunits and chloride channels are not as consistent (Figure 3-8b,c), which makes it 
difficult to interpret whether there could be differences in those proteins in patients with 
CDD. However, the GluA2:GluA1 data suggests that our findings in the mouse may 
indeed be clinically relevant, though further investigation is necessary.   
Discussion 
Here we observed a specific decrease in GluA2 and GluA2:GluA1 in the hippocampus, 
but not cortex, of R59X mice beginning at P30 and persisting throughout adulthood. No 
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significant alterations in GluA1, GluN2A, GluN2B, NKCC1 or KCC2 were found in the 
hippocampus or cortex of R59X mice. Our Western blot results are supported by surface 
GluA1 and GluA2 staining colocalized with presynaptic marker synapsin in hippocampal 
slices, which showed a significant decrease in GluA2-containing synapses in CA1 s. 
radiatum as well as DG hilus. Interestingly, we did not observe a significant decrease in 
GluA2 in CA3 s. radiatum. It is challenging to fully understand these region-specific 
changes without further knowledge of the cell types involved and the function of CDKL5 
within those cell types. However, our immunohistochemistry analysis was not 
comprehensive in looking at the entire hippocampus and it is possible that we missed 
GluA2 changes occurring in other areas within CA3. Finally, we observed a trend 
towards decreased GluA2:GluA1 in two post-mortem cases of CDD and no strong trends 
in NMDAR subunits or Cl- channels, indicating that our findings may be clinically relevant 
in the CDD patient population.  
Decreased GluA2:GluA1 suggests an increase in GluA2-lacking AMPARs at the 
membrane. The GluA2 subunit is critical in determining biophysical properties of 
AMPARs including rectification, single channel conductance, and Ca2+ permeability 
(Kumar et al., 2002; Isaac et al., 2007; Migues et al., 2007). Furthermore, decreased 
surface GluA2 has been observed to contribute to hyperexcitability, altered plasticity, 
and intellectual disability, implicating GluA2-lacking AMPARs as a critical player in 
neuronal function and disease (Gardner et al., 2005; Mignogna et al., 2015; Lorgen et 
al., 2017). Thus, increased GluA2-lacking AMPARs in R59X hippocampus CA1 and DG 
53 
 
may be contributing to the behavioral deficits and hyperexcitability observed at the whole 
animal level. 
Our lab has previously observed increased GluA2-lacking AMPARs in a rat model of 
early-life epilepsy 48 hours after hypoxic seizures (Sanchez et al., 2001; Rakhade et al., 
2012; Lippman-Bell et al., 2016). Furthermore, blocking AMPAR activity with NBQX 
immediately after seizures in this model prevented later-life epileptic seizures and 
autistic-like social deficits (Lippman-Bell et al., 2013), suggesting that early intervention 
of elevated GluA2-lacking AMPAR activity may inhibit development of hyperexcitable 
and autistic-like phenotypes. GluA2 dysregulation has additionally been observed in 
Fragile X Syndrome and Rett Syndrome (Li et al., 2016; Achuta et al., 2018).  
Recently, glutamate receptor subunit levels have been investigated in two other models 
of CDD. Interestingly, decreased surface GluA2:GluA1 was also observed in a cell 
culture model of CDD where Cdkl5 was silenced in primary hippocampal cultures using 
shRNA (Tramarin et al., 2018). However, our data conflicts with a study in a knock-out 
mouse model of CDD where investigators observed a significant increase in GluN2B 
subunits in the hippocampus, which they show also contributes to hyperexcitability at the 
whole animal level (Okuda et al., 2017). The difference in results of GluN2B may be due 
to the disparate genetic backgrounds of the mouse models used by each study as well 
as the techniques used to measure glutamate receptor subunit expression. The GluN2B 
differences in the knock-out model were observed in the PSD-1T fraction of tissue and 
by immunogold labeling of CA1 stratum radiatum rather than membrane prepped tissue 
and standard immunohistochemistry performed here. Further experiments must be 
54 
 
performed in R59X tissue to determine whether increased GluN2B may be observed 
with more precise techniques.  
Although membrane-bound GluA2:GluA1 is significantly decreased in adult R59X mice, 
we did not observe a similar trend in relative mRNA expression of Gria1 and Gria2, 
suggesting that loss of CDKL5 results in disrupted trafficking or localization of GluA2 to 
the membrane. These findings mirror those of the primary hippocampal cell culture 
model of CDD where they found no change in mRNA levels  (Tramarin et al., 2018). 
However, contrary to our results, the cell culture model exhibited significantly decreased 
total GluA2, which was accompanied by increased GluA2S880 suggesting increased 
internalization of the subunit. The differences in these results may be due to the 
heterogenous cell population of tissue samples used for our Western blotting 
experiments versus the pure neuronal cell population studied in the cell culture model. 
The mixed cell population in our experiments may also be diluting any potential 
differences in the trafficking proteins PICK1 or RAB39B that may be contributing to 
decreased membrane-bound GluA2. However, another mechanism for impaired synaptic 
localization of GluA2 may be through dysregulation of PSD95, a molecule involved in 
clustering of AMPARs through interaction with scaffolding protein stargazin/TARP (Coley 
and Gao, 2017). A reduction of PSD-95 puncta has been observed in neurons after 
CDKL5 knock-down (Ricciardi et al., 2012; Tramarin et al., 2018), suggesting that 
anchoring and stability of glutamate receptors at the synapse may be compromised in 
this disorder. Interestingly, palmitoylation of PSD-95 recruits CDKL5 to synapses  (Zhu 
et al., 2013) and has also been found to increase surface GluA2 levels  (Jeyifous et al., 
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2016), suggesting a possible link between CDKL5 function and GluA2 localization at the 
synapse. A deeper understanding of CDKL5 interacting partners and phosphorylation 
substrates is necessary to identify the primary cause of dysregulated synaptic GluA2 
and its functional consequences.  
Materials and Methods 
Western Blotting 
To compare developmental expression patterns of AMPA receptor subunits GluA1 and 
GluA2, R59X and WT littermates were sacrificed at P7, P14, P21, P30, P50, and P125. 
Brains were rapidly dissected from the skull, and hippocampal and cortical regions were 
separated. Tissue was flash-frozen in chilled ethanol and stored at -80°C until 
homogenization. Membrane and whole cell protein extraction from the anterior two-thirds 
of the cortex and the entire hippocampal tissue was performed as described previously  
(Wenthold et al., 1992; Talos et al., 2006; Rakhade et al., 2012). Halt Protease and 
Phosphatase Inhibitor Cocktail EDTA-free (Thermo Fisher) and PMSF (Thermo Fisher) 
were added to inhibit proteases and phosphatases. Total protein concentrations were 
measured by the Bradford protein assay (Bio-Rad) and samples were diluted to obtain 
equal amounts of protein for each sample (1µg/ul). Samples were separated by gel 
electrophoresis on Criterion TGX 4-20% precast gels and transferred to PVDF 
membranes (Immobilon-FL). Primary antibodies used in this study were GluA2 (1:1000; 
Millipore; MAB397), GluA1 (1:1000; Abcam; ab31232), NR2A (1:1000, Sigma; M264), 
NR2B (1:1000, Thermo-Fisher; MA1-2014), NKCC1 (1:1000, Millipore), KCC2 (1:1000, 
Abcam) and β-actin (1:3000; Sigma; A5441). Secondary antibodies used were rabbit 
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IRDye 800CW and mouse IRDye 680LT (Licor). The Odyssey Infrared Imaging System 
protocols were used for blots and quantification of protein expression. Protein levels 
were normalized to the P50 time point.  
Immunohistochemistry 
P50 WT and R59X mice were perfused transcardially with 4% paraformaldehyde. Brains 
were dissected from the skull and post-fixed for 1 hour at room temperature before being 
transferred to 30% sucrose. Once saturated with sucrose, the brains were embedded in 
OCT and frozen. 16 µm sections were collected using a cryostat and mounted on slides. 
Sections containing the middle 1/3 of the hippocampus were blocked with 10% normal 
goat serum in PBS and incubated with either anti-GluA2 (extracellular, 1:500, Millipore) 
or anti-GluA1 (extracellular, 1:500, NeuroMab) overnight, then incubated with AlexaFluor 
secondary (1:1000, Invitrogen) for 1 hour at room temperature. Sections were then 
permeabilized with 0.2% Triton X-100 in PBS for 5 minutes and then blocked with 10% 
normal goat serum (NGS) with 0.1% Triton in PBS for 1 hour. Finally, the sections were 
incubated with anti-synapsin (1:1000, Millipore) diluted in 0.1% NGS and 0.1% Triton in 
PBS overnight at 4°C, washed with PBS, and incubated with AlexaFluor secondary 
(1:1000, Invitrogen) for 1 hour at room temperature. Fluoromount with Dapi was used to 
mount the sections with a coverslip. Sections incubated without primary and only with 
secondary antibody were imaged to verify antibody specificity. We have previously 
confirmed the surface specificity of the GluA2 antibody used here in permeabilized and 
non-permeabilized sections incubated with an antibody to MAP2 (1:1000, Millipore) in 
addition to GluA2 (Lippman-Bell et al., 2016). Blinded sections were placed on a Zeiss 
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LSM710 confocal microscope with an oil-immersion 63x1.7 NA objective. Z-stacks for all 
images were 0.25 µm.  
Analysis of z-stacks was performed blindly using Image-J software. To avoid a 
thresholding artifact, colocalization was first measured at the maximum threshold 
incorporating all GluA2 puncta, then the GluA2 channel was thresholded at multiple 
intervals of the max threshold (95, 90, 85, 80, 75, and 70%), and colocalization was 
determined again at each threshold (Nie et al., 2010; Zhou et al., 2011). After 
thresholding each channel, the overlap of GluA2 with synapsin puncta was quantified 
using the plugin coloc2 to determine the Manders coefficient (Manders et al., 1993).   
RT-qPCR 
P50 mice were sacrificed and whole hippocampus was collected. RNA was isolated 
using Qiagen RNeasy kit and then converted to cDNA with Invitrogen SuperScript III 
First-Strand Synthesis System. RT-qPCR was run using TaqMan optimized primer probe 
sets—for GRIA1, GRIA2, ACTB (b-actin), and HPRT—and TaqMan Master Mix.  
Experimental design and statistical analysis 
We determined sample size and power for Western blots and immunohistochemistry 
based on previously published work in our laboratory (Rakhade et al., 2012; Lippman-
Bell et al., 2016). The number of mice used in each experiment was predetermined 
before the start of the experiment.   
Stastical analysis was completed using GraphPad Prism. All datasets were analyzed 
using the D’Agostino–Pearson test for normality. Datasets with normal distributions were 
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analyzed for significance using unpaired Student’s two-tailed t test. Two-way repeated-
measures ANOVA was conducted for comparing mean differences between groups that 
have been split on two independent variables with Holm–Sidak’s multiple-comparison 
test. 
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Figures 
Figure 3-1 
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Figure 3-1. AMPAR subunit GluA2 and ratio of subunits GluA2:GluA1 are 
significantly decreased at developmental time points P30, P50 and P125 in R59X 
hippocampus. a. Levels of GluA1 are not significantly altered at any time point. Multiple 
t tests. b. Levels of GluA2 are significantly decreased at P30, P50, and P125. Multiple t 
tests, P30: p=0.0089, P50: p=0.0053, P125: p=0.0193 c. Levels of GluA2:GluA1 are 
significantly decreased at P30, P50, and P125. Multiple t tests, P30: p=0.0180, P50: 
p=0.0002, P125: p=0.0048 d-f. Developmental curve of GluA1. Two-way ANOVA, 
p=0.99. e. Developmental curve of GluA2. Two-way ANOVA with Sidak’s multiple 
comparisons, interaction p=0.0250. f. Developmental curve of GluA2:GluA1. Two-way 
ANOVA with Sidak’s multiple comparisons, interaction p=0.0440. d. Representative 
Western blots of GluA1 and GluA2 compared to actin loading control. e-g. No change in 
AMPAR subunits in R59X cortex. Two-way ANOVA, GluA1: p=0.891, GluA2: p=0.999, 
GluA2:GluA1: p=0.928. h. Representative Western blots of AMPAR subunits compared 
to actin loading control. N=8-12 for all time points. All time points in a-c normalized to 
age-matched WT controls All time points in d-j normalized to WT P50. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 3-2 
 
Figure 3-2: No alterations in NMDAR subunit levels in R59X cortex and 
hippocampus over development. a-c. Developmental expression of GluN2A, GluN2B, or 
GluN2B:2A is not altered in R59X hippocampus. Two-way ANOVA, GluN2A: p=0.672, GluN2B: 
a. b. c.
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p=0.852, GluN2B:N2A: p=0.696. d. Representative Western blots of GluN2A and GluN2B 
compared to actin loading control. e-g. No change in NMDAR subunits in R59X cortex. Two-way 
ANOVA, GluN2A: p=0.703, GluN2B: p=0.780, GluN2B:2A p=0.991 h. Representative Western 
blots of NMDAR subunits compared to actin loading control. N=8-12 for all time points. All time 
points normalized to WT P50. 
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Figure 3-3 
 
Figure 3-3: No alterations in chloride transporters NKCC1 or KCC2 levels in R59X 
cortex or hippocampus over development. a-c. Developmental expression of NKCC1 and 
KCC2 is not altered in R59X hippocampus. Two-way ANOVA, NKCC1: p=0.992, KCC2 (total): 
p=0.799, NKCC1:KCC2: p=0.908. d. Representative Western blots of NKCC1 and KCC2 
a. b. c.
d.
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(monomer and dimer bands) in hippocampus compared to actin loading control. e-g. No change 
in chloride channels NKCC1 or KCC2 over development in R59X cortex. Two-way ANOVA, 
NKCC1: p=0.644, KCC2: p=0.519, NKCC1:KCC2: p=0.833. h. Representative Western blots of 
NKCC1 and KCC2 (monomer and dimer bands) in cortex compared to actin loading control. N=8-
12 for all time points. All time points normalized to WT P50.  
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Figure 3-4 
 
Figure 3-4: Fraction of GluA2-containing synapses is significantly decreased in 
CA1. a. Immunohistochemistry of surface GluA2 (green) and presynaptic marker 
synapsin (red) in CA1. b. Quantification shows a significant decrease in the fraction of 
synapsin puncta that colocalize with GluA2, representative of decreased synaptic GluA2 
in CA1. Unpaired t test, p=0.003. c,d. Synaptic GluA1 is not significantly altered in R59X 
CA1 s. radiatum. Unpaired t test, p=0.24. Circles highlight colocalization and arrowheads 
mark synapsin without GluA2. N=10 fields from 5 mice for all groups. ** p<0.01.  
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Figure 3-5 
 
Figure 3-5: Fraction of synapses containing GluA2 is significantly decreased in 
DG. a. Immunohistochemistry of surface GluA2 (green) and presynaptic marker 
synapsin (red) in DG. b. Quantification shows a significant decrease in the fraction of 
synapsin puncta that overlap with GluA2, representative of decreased synaptic GluA2 in 
DG hilus. Unpaired t test, p=0.01. c,d. Synaptic GluA1 is not significantly altered in DG 
hilus. Unpaired t test, p=0.06. Circles highlight colocalization and arrowheads mark 
synapsin without GluA2. N=10 fields from 5 mice for all groups. * p<0.05.  
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Figure 3-6 
 
Figure 3-6: No change in fraction of synapses containing GluA2 or GluA1 in CA3. 
a,b. Synaptic GluA2 is not significantly altered in CA3. Unpaired t test, p=0.22. c,d. 
Synaptic GluA1 is not significantly altered in CA3. Unpaired t test, p=0.16. Circles 
highlight colocalization and arrowheads mark synapsin without GluA2. N=10 fields from 
5 mice for all groups. 
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Figure 3-7 
 
Figure 3-7: No change in fraction of synapses containing GluA2 or GluA1 in cortex 
layer II/III. a,b. Synaptic GluA2 is not significantly altered in layer II/III. Unpaired t test, 
p=0.12. c,d. Synaptic GluA1 is not significantly altered in II/III. Unpaired t test, p=0.10. 
Circles highlight colocalization and arrowheads mark synapsin without GluA2. N=10 
fields from 5 mice for all groups. 
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Figure 3-8 
 
Figure 3-8. Western blot analysis in post-mortem hippocampal tissue from 
patients with CDD. a. Trend towards decreased GluA2 and GluA2:GluA1 in both post 
mortem disease cases. b. No observable trend in NMDAR subunits or subunit ratio. c. 
No observable trend in levels or ratio of chloride transporters. 
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Tables 
Table 3-1 
mRNA or protein WT  R59X  n P value 
Gria1 1.00 ± 0.046 1.03 ± 0.069 8 0.788 
Gria2 1.00 ± 0.054 1.07 ± 0.087 8 0.587 
GluA1 (total) 100.000 ± 8.46 98.74 ± 8.48 8 0.918 
GluA2 (total) 100.000 ± 9.22 97.27 ± 8.37 8 0.830 
GluA2:GluA1 100.000 ± 2.13 99.13 ± 2.66 8 0.803 
GluA2S880/total 100.000 ± 3.41 98.49 ± 7.71 14 0.935 
PICK1 100.000 ± 6.55 103.00 ± 6.73 8 0.754 
RAB39B 100.000 ± 9.16 105.59 ± 9.75 8 0.685 
CaMKII 100.0 ± 6.027 99.85 ± 5.607 13 0.985 
 
Table 3-1: Normalized mRNA and protein levels of GluA1, GluA2 and associated trafficking 
proteins in whole cell hippocampal lysate. No significant changes were found in GluA1 or GluA2 
mRNA levels (Gria1 and Gria2 respectively) in R59X mice. Whole cell levels of GluA1 and GluA2 
and were also not altered in R59X hippocampus. We thus investigated levels of phosphorylated 
GluA2 at Ser880 (GluA2S880), which sequesters GluA2 in intracellular pools, and several proteins 
involved in GluA2 trafficking: PICK1, RAB39B, and CaMKII. No significant alterations were found 
in GluA2S880/total or the GluA2 trafficking proteins in R59X hippocampus. 
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Table 3-2 
 CDD cases compared to age-
matched neurotypical controls 
Protein Temporal Hipp 
GluN2A - 0 
GluN2B - - 0 
GluN2B:2A - 0 
GluA1 - - 0 
GluA2 - - - - 
GluA2:GluA1 - - - 
NKCC1 + + 
KCC2 - + 
NKCC1:KCC2 + 0 
GABAA a1 0 0 
GABAA a3 0 0 
GABAA a3:a1 0 0 
Table 3-2: Temporal and hippocampal tissue from two human CDD cases. Cases were 
aged 5 and 30, and were compared to three age-matched neurotypical controls each 
and probed for NMDAR receptor subunits GluN2A and GluN2B, AMPAR subunits GluA1 
and GluA2, chloride channels NKCC1 and KCC2, and GABAA subunits a1 and a3. 
Trends are denoted with “+“ or “-” to symbolize an increase or decrease respectively with 
larger magnitude of the increase or decrease represented by increasing number of 
symbols. Proteins with no discernible trend are marked with “0”. 
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CHAPTER 4 – Functional analysis in hippocampal slices  
Introduction 
Our Western blot and immunohistochemical data suggests increased levels of 
membrane-associated GluA2-lacking AMPARs at hippocampal CA1 synapses in R59X 
mice, so we sought to verify whether the molecular changes are accompanied by 
functional alterations through extracellular and whole-cell patch clamp recordings in 
hippocampal slices.  
Electrophysiology explores the electrical activity of living neurons, either in cell culture or 
brain slices, and is an excellent technique to understand neuronal circuitry and 
underlying mechanisms of plasticity such as long-term potentiation (LTP) and long-term 
depression (LTD). For extracellular recordings, field excitatory post synaptic potentials 
(fEPSPs) are generated from the activity of a group of neurons and recorded using a 
glass electrode placed directly onto the slice. Synaptic activity is evoked by delivering a 
pulse of current with a stimulating electrode placed a short distance away from the 
recording electrode. Extracellular recordings are useful for studying network dynamics 
and plasticity. For example, the input-output (I-O) curve is used to measure the basal 
network excitability of a slice and is obtained by simulating the slice with increasing 
current intensities and measuring the slope or amplitude of fEPSPs at each current. I-O 
function is then used to determine the intensity of current used for other paradigms such 
as the paired pulse ratio (PPR), LTP, and LTD. Typically, 50-60% of the current intensity 
that elicits the max response in the I-O curve is used. To determine PPR, a conventional 
measure of presynaptic function, pulses are delivered at various inter-stimulus intervals 
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(ISIs), ranging from 5 to 500 ms, and the ratio of the 2nd:1st fEPSP is plotted against the 
ISIs. Paired pulse facilitation is commonly observed, where the second fEPSP will be 
greater than the first due to a higher neurotransmitter release probability due to the Ca2+ 
accumulation in presynaptic terminals  (Fioravante and Regehr, 2011). Thus, if there are 
variations in PPR it is attributed to altered presynaptic function. Extracellular recordings 
may also be used to probe activity-dependent forms of synaptic plasticity such as LTP 
and LTD by delivering patterned stimulation to the slice.  
In whole-cell voltage patch-clamp recordings, current is recorded from an individual cell 
in the slice rather than fEPSPs from a collection of cells. A glass pipette filled with 
solution that mimics intracellular environment is used to break the membrane of a cell, 
which allows electrical access to the interior of the cell and changes in current are 
measured by holding the membrane at various voltages. Whole-cell patch clamp 
recordings allow for analysis of isolated AMPAR or NMDAR-mediated currents over 
different holding potentials by pharmacologically inhibiting one or the other, along with 
GABA receptors. The AMPAR-mediated current-voltage (I-V) plot is used to verify 
functional surface populations of GluA2-lacking AMPARs due to their characteristic 
inward rectification at high voltage potentials. GluA2-lacking AMPARs are subject to 
intracellular spermine block at high voltages resulting in decreased current to flow 
through the channel and inward rectification (Isaac et al., 2007), which can be blocked 
with GluA2-lacking specific blocker IEM-1460 (Buldakova et al., 2007).  
Given that increased GluA2-lacking AMPARs are typically accompanied with 
electrophysiological alterations (Jia et al., 1996; Lippman-Bell et al., 2016), we 
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investigated whether decreased GluA2 in R59X mice results in functional alterations in I-
O curve, PPR, LTD, and LTP at Schaffer collateral-CA1 synapses in the hippocampus. 
All electrophysiology experiments were performed by Rachel White, PhD with 
experimental design input by Madhu Yennawar and Frances Jensen.  
Results 
Extracellular recordings reveal normal I-O function, PPR, and LTD, but elevated 
LTP in R59X mice 
Given the hippocampal-associated memory deficits and molecular changes in R59X 
mice, we aimed to determine whether R59X mice exhibit alterations in synaptic plasticity 
by performing extracellular field recordings in ex vivo hippocampal slices. We chose the 
P30 time point for electrophysiological experiments because it was the earliest time point 
that significant GluA2 deficits were observed in the Western blot. First, we observed no 
change in input-output (I-O) function (Fig. 4-1a) or PPR (Fig. 4-1b), suggesting that both 
basal synaptic function and presynaptic function are unaltered at Schaffer collateral-CA1 
synapses. Next, we tested synaptic plasticity by evaluating LTD and LTP. LTD was 
induced using low-frequency stimulation (LFS) and found to be unaltered in R59X mice 
(Fig 4-1c). In the LTP paradigm, however, R59X mice responded significantly differently 
to high frequency stimulation (HFS) compared to controls (Fig 4-1d. Two-way ANOVA, 
main effect of genotype, p<0.0001); mutant mice displayed significantly elevated early-
phase potentiation 15 min post-HFS (Unpaired t test, R59X: 188.7 ± 14.88, vs WT: 136.8 
± 9.911, p=0.0125) followed by a steeper decay slope (Linear regression, R59X: -1.192 
± 0.1071 vs WT: -0.1192 ± 0.08017 p<0.0001), resulting in R59X activity approximately 
reaching WT levels of potentiation by 60 min post-HFS.  
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Whole-cell patch clamp recordings show inward rectification of AMPAR-mediated 
currents  
To more directly examine the functional consequence of GluA2 deficiency in R59X mice, 
we performed whole-cell patch clamp recordings in CA1 pyramidal neurons to observe 
whether the responses in the AMPAR I-V relationship in R59X mice showed inward 
rectification, a hallmark characteristic of an increased population of GluA2-lacking 
AMPARs (Kamboj et al., 1995; Washburn et al., 1997; Lippman-Bell et al., 2016). Cells 
were held at potentials from -80 to +40 mV and the observed current at each holding 
potential was recorded. R59X mice displayed significantly greater inward rectification in 
the I-V plot at +20 and +40 mV holding potentials (Fig. 4-2a. Two-way ANOVA, 
F6,105=7.074, interaction p<0.000, Sidak’s multiple comparison test: +20 mV, R59X: 
0.176 ± 0.03 vs WT: 0.367 ± 0.029; +40 mV, R59X: 0.299 ± 0.025 vs WT: 0.614 ± 0.058) 
and a significantly greater rectification ratio (-60/+40 mV) of AMPAR-mediated EPSCs in 
slices from mutant mice compared to controls (Fig. 4-2b. Unpaired t test, R59X: 2.55 ± 
0.194 vs WT: 1.46 ± 0.136). Input resistance was not altered between R59X mice and 
WT littermates (data not shown), suggesting that cell size does not vary significantly between 
genotypes. Taken together with the elevated early-phase LTP, these data demonstrate a 
physiologically relevant increase in hippocampal GluA2-lacking AMPARs in R59X mice.  
Discussion 
Our whole cell patch recordings reveal significant inward rectification of AMPAR currents 
in R59X mice at higher voltages, which is a hallmark characteristic of GluA2-lacking 
AMPARs due to their susceptibility to voltage-dependent spermine block (Isaac et al., 
2007; Liu and Zukin, 2007). Inward rectification in the I-V plot supports our Western blot 
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results that suggest increased GluA2-lacking AMPARs in the hippocampus of R59X 
mice due to decreased ratio of GluA2:GluA1 subunits. Furthermore, the I-V data 
suggests that the increased population of GluA2-lacking AMPARs is functionally relevant 
in CA1 and thus may contribute to the altered plasticity observed in extracellular 
recordings.  
Our extracellular recordings showed that mutant mice exhibit significantly elevated early-
phase LTP at Schaffer collateral-CA1 synapses. Previous reports by others have shown 
impaired LTP, induced by theta-burst stimulation, in cortex layer II-III in CDKL5 KO mice 
(Della Sala et al., 2016). We did not investigate LTP in this region as our molecular and 
functional analyses focused on hippocampal alterations. However, is possible that loss 
of CDKL5 affects LTP differentially in the cortex and hippocampus due to variations in 
cell populations and circuit dynamics. Indeed, more recently in a different CDKL5 KO 
mouse, LTP induced by tetanic stimulation was observed to be significantly elevated in 
the hippocampus. Interestingly, in contrast to our results where elevated early-phase 
potentiation declined to WT levels 60 minutes post-HFS, elevated potentiation in CDKL5 
KO mice was sustained throughout the 60 minutes post-tetanus. One reason for this 
may be that the induction paradigms between these results differs slightly; in our 
experiment LTP was induced by 4 trains of 100 Hz stimulation for 1 second, 20 seconds 
apart and in the CDKL5 KO mice LTP was induced with one 100 Hz burst for 1 second. 
Although these two stimulation paradigms have not been directly compared in the 
literature, it has been observed that different stimulation paradigms such as high 
frequency stimulation and theta burst stimulation can result in varied magnitudes of 
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potentiation as well as activation of distinct intracellular signaling pathways, contributing 
to differences in results (Hernandez et al., 2005; Larson and Munkácsy, 2015; Zhu et al., 
2015). GluA2 KO mice also display elevated LTP that is sustained throughout the 
recording period (Jia et al., 1996), perhaps due to the even greater levels of GluA2-
lacking AMPARs that are present in GluA2 KO mice compared to R59X mice.  
Indeed, GluA2-lacking AMPARs are normally crucial for LTP induction and are inserted 
into the synaptic membrane immediately following HFS. They are gradually replaced by 
GluA2-containing AMPARs at the synapse during the consolidation phase of LTP (40-60 
min post-HFS; Plant et al., 2006; Jaafari et al., 2012; Hanley, 2014). Thus, the elevated 
potentiated response in R59X mice 15 min-post HFS is likely a result of 1) elevated 
basal levels of GluA2-lacking AMPARs at the synapse and 2) additional insertion of 
GluA2-lacking AMPARs that normally occurs during the induction phase of LTP. 
Data from our extracellular recordings in R59X hippocampal slices indicate that mutant 
mice have normal I-O function and PPR compared to slices from WT controls. Observing 
normal baseline network activity in mutant mice is not surprising, as at the whole animal 
level R59X mice did not exhibit visible spontaneous seizures and required provocation 
with pentylenetetrazol to demonstrate hyperexcitability. Furthermore, a recent study in 
CDKL5 KO mice also did not report altered I-O function in hippocampal slices (Okuda et 
al., 2017). Our PPR data showing normal presynaptic function in R59X hippocampus 
was also expected, as the majority of the literature describing cell culture and animal 
models of CDD indicate that loss of CDKL5 results in post-synaptic deficits such as 
decreased PSD-95 and spine and dendritic abnormalities  (Zhu et al., 2013; Amendola 
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et al., 2014; Fuchs et al., 2014; Della Sala et al., 2016), although we ourselves have not 
yet investigated presynaptic proteins in R59X mice. Finally, a GluA2 KO mouse model 
also exhibited normal I-O function and PPR in the hippocampus (Jia et al., 1996), 
corroborating our results.   
Finally, although GluA2 is important for LTD (Chater and Goda, 2014) we did not 
observe abnormal LTD in R59X mice, similar to other models with GluA2 deficits (Jia et 
al., 1996; Meng et al., 2003) suggesting that GluA2 may not be required for LTD in all 
cases. Additionally, PICK1-mediated AMPAR endocytosis is reported to be involved with 
LTD expression (Rocca et al., 2013), and PICK1 levels are not significantly altered in 
R59X hippocampus (see Chapter 3, Table 1), indicating that this step of LTD induction is 
likely normal in R59X mice. 
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Materials and Methods 
Hippocampal slice preparation 
P28-32 R59X and WT animals were decapitated and brains rapidly dissected from the 
skull and placed for section in ice-cooled cutting solution containing the following (in mM)  
220 sucrose, 3 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 1 MgCl2, 26.19 NaHCO3, and 10 D-
glucose, pH 7.4, 295-305mOsm bubbled with 95%O2/5%CO2 at 4°C. Coronal 
hippocampal slices (350 µm thickness) were sectioned from the middle third of 
hippocampus with a vibratome (Leica VT1000S) in cutting solution. Slices were 
incubated for 30 min at 32 degrees C followed by at least 30 min at room temperature in 
oxygenated artificial cerebrospinal fluid (ACSF), containing the following (in mM): 130 
NaCl, 3 KCl, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, 26 NaHO2, 10 D-glucose, pH 7.4, 295-
305mOsm, bubbled with 95%O2/5%CO2.  
Extracellular field recordings 
Slices were transferred to the recording chamber with ACSF heated to 32 degrees C 
and Schaffer collaterals from CA3 to CA1 were stimulated at 30 sec intervals to obtain 
input-output curves. Stimulus intensity (0.1 msec in duration) that evoked 60-70% 
maximal slope response was used for paired pulse ratio and LTD and LTP induction. 
Paired-pulse stimuli were delivered at interstimulus intervals ranging from 5 to 500 ms, 
and the degree of paired-pulse inhibition or facilitation was calculated for each interval. 
For paired-pulse analysis, a ratio of the second response amplitude to that of the first 
was used. At a given interstimulus interval, a ratio >1 indicated paired-pulse facilitation 
and a ratio <1 indicated paired-pulse inhibition. Finally, baseline responses were 
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recorded every 30 s for 10–20 min. After a stable baseline of ≥10 min, either LTD or LTP 
was induced. LTP was induced by high frequency stimulation (4 stimuli at 100-Hz, 1-s 
duration, repeated 20 s apart) (Jensen et al., 1998). After tetanus, single half-maximal 
stimuli were applied every 30 s for 60 min in all slices. The percent change in fEPSP 10-
90% slope was calculated after tetanus compared with pre-tetanus baseline. To induce 
LTD low-frequency (LFS) stimuli protocol consisted of 1800 shocks at 2Hz for 15mins  
(Lippman-Bell et al., 2016).  
Whole-cell patch-clamp 
Whole-cell patch-clamp recordings from hippocampal CA1 pyramidal neurons in brain 
slices using infrared- differential interference contrast microscope as described 
previously  (Rakhade et al., 2008). The patch-pipette internal solution contained the 
following (in mM): 110 Cs-methanesulfonate, 10 TEA-Cl, 4 NaCl, 2 MgCl2, 10 EGTA, 10 
HEPES,  4 ATP-Mg, and 0.3 GTP, pH 7.25, 5 QX-314, 7 phosphocreatine, creatine 
phosphokinase (17 unit/ml) and 0.1 spermine, 280-290mOsm. Filled electrodes had 
resistances of 2–5 MΩ. Evoked (e) EPSCs were elicited at 10 s intervals. Picrotoxin 
(100µM) or AP5 (50µM) were added to block GABA receptors or NMDA receptors 
respectively for the I-V recordings. To collect evoked AMPA receptor currents for I-V 
curves cells were held from -80mV to +40mV and evoked by stimulating the Schaffer 
collaterals. The data were obtained from the average max amplitude from 3-4 recordings 
per holding voltage (Vh). Data were collected using an Axopatch200B amplifier 
(Molecular Devices Inc., Union City, CA, USA) and Clampex 9.2 software (Molecular 
Devices Inc., Union City, CA, USA) with compensation for series resistance (70%) and 
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cell capacitance, filtered at 2 kHz, and digitized at 20 kHz using a Digidata 1320A analog 
to digital converter (Molecular Devices Inc., Union City, CA, USA). 
Experimental design and statistical analysis 
For electrophysiology, we chose sample sizes based on previously published results 
from our lab (Zhou et al., 2011; Lippman-Bell et al., 2016)  
Stastical analysis was completed using GraphPad Prism. All datasets were analyzed 
using the D’Agostino–Pearson test for normality. Datasets with normal distributions were 
analyzed for significance using unpaired Student’s two-tailed t test. Two-way repeated-
measures ANOVA was conducted for the appropriate datasets with Holm–Sidak’s 
multiple-comparison test. Linear regression analysis was used to determine decay 
slopes in the LTP experiments.  
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Figures 
Figure 4-1 
 
Figure 1. Extracellular recordings in R59X mice show no change in IO function, 
paired-pulse ratio, or LTD but elevated early-phase LTP. a. R59X mice have normal 
input-output function (N=16). b. Paired-pulse ratio, a conventional measure of 
presynaptic function, is not altered in R59X mice (N=22-27). c. LTD is normal in R59X 
mice (N=10). d. R59X display abnormal LTP. Two-way ANOVA, main effect of genotype, 
p<0.0001, with significantly elevated potentiation at 15 min post-HFS and steeper decay 
slope. Unpaired t test,* p<0.05, and linear regression, p<0.0001. N=6-7  
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Figure 4-2 
 
 
Figure 2. Whole-cell electrophysiology recordings verify increased population of 
GluA2-lacking AMPARs at CA1 synapses. a. CA1 pyramidal neurons in R59X mice 
exhibit significant inward rectification at +20 and +40 mV, characteristic of GluA2-lacking 
AMPARs. Two-way ANOVA with Sidak’s multiple comparisons, interaction p<0.0001 b. 
Rectification ratio is significantly elevated in R59X mice. Unpaired t-test, p<0.001 c. 
Representative traces at -60 and +40 mV. N=8-9, *p<0.05, ***p<0.001, ****p<0.0001 
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CHAPTER 5 – Therapeutic effects of GluA2-lacking AMPAR blocker 
IEM-1460 in R59X mice 
Introduction 
There is currently no therapy to slow or halt disease progression in patients with CDD. 
Furthermore, seizures in CDD are largely refractory to traditional anti-epileptic drugs, 
although valproate and vigabatrin are typically administered for infantile spasms and 
levetiracetam and topiramate are often used in later stages of myoclonic and multifocal 
epilepsy (Bahi-Buisson and Bienvenu, 2012). These drugs are commonly used in 
infantile and pediatric patients with epilepsy, and are not targeted to CDD-specific 
protein dysregulation.  
Because our molecular and functional analysis identified increased GluA2-lacking 
AMPARs in the hippocampus in R59X mice, we decided to test whether specifically 
blocking this receptor subtype with GluA2-lacking AMPAR blocker IEM-1460 (Samoilova 
et al., 1999) would have therapeutic effects on behavioral deficits and lowered seizure 
threshold in mutant mice. IEM-1460 has been observed to exert anti-epileptic effects in 
rats but has not been tested in behavioral assays evaluating social behavior or learning 
and memory. However, we have previously showed that blocking AMPARs immediately 
post-seizure in a rat model of early-life epilepsy prevented development of later-life 
social deficits and epileptogenesis (Lippman-Bell et al., 2013), suggesting that blocking 
AMPARs may be therapeutic in mouse models of autism and hyperexcitability. AMPAR 
blockers are not currently used to treat patients with CDD.  
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Few studies have evaluated therapeutic intervention on behavioral phenotypes in mouse 
models of CDD. Chronic administration of two GSK3b inhibitors, SB216763 and FDA-
approved Tideglusib, exhibits efficacy in rescuing working and spatial memory deficits 
respectively in CDKL5 KO mice (Fuchs et al., 2015, 2018). Another group found that 
ifenprodil reduced NMDA-induced seizure severity in CDKL5 KO mice (Okuda et al., 
2017) but did not evaluate the effects on ifenprodil on behavioral deficits in their model.  
We show that acute treatment of IEM-1460 results in significant therapeutic effects on 
social behavior, short-term memory, and hyperexcitability in R59X mice. These results 
suggest that increased GluA2-lacking AMPARs found in R59X hippocampus could be 
contributing to altered behavioral phenotypes in R59X mice. Furthermore, the data 
suggest that blocking GluA2-lacking AMPARs may be a novel therapeutic strategy in 
CDD not only for hyperexcitability, but for impairments in behavior and social interaction 
as well.  
Results 
IEM-1460 rescues social behavior deficits and working memory in R59X mice 
Because GluA2-lacking AMPARs are implicated in autism and intellectual disability  
(Isaac et al., 2007; Mignogna et al., 2015; Lippman-Bell et al., 2016), we sought to 
determine if specifically blocking GluA2-lacking AMPARs attenuates behavioral deficits 
and memory in R59X mice. Mutant mice and WT littermates were treated with GluA2-
lacking AMPAR-specific blocker IEM-1460 (10 mg/kg, i.p.) one hour before behavioral 
tests (Magazanik et al., 1997; Szczurowska and Mareš, 2015). IEM-1460 caused both 
WT and R59X animals to be mildly hypoactive during the first 8 minutes of the open field 
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test (data not shown, Two-way ANOVA with Sidak’s multiple comparisons, F27, 310 = 
3.441, interaction p<0.0001). However, by minutes 9 and 10 there were no significant 
differences in number of beam breaks between treatment groups. In the social choice 
assay, drug treatment rescued R59X duration of time sniffing to saline treated WT levels 
(Fig. 5-1a, Two-way ANOVA F3,76= 8.947, interaction p<0.0001), while also increasing 
the time spent directly interacting with the novel mouse (Fig. 5-1b, One-way ANOVA, 
F3,38 = 10.71, p<0.0001). In the Y maze, IEM-1460 rescued % SAB in R59X mice to WT 
levels (Fig. 5-1d. One-way ANOVA, F3,33=14.06, interaction p<0.0001) suggesting that 
blocking GluA2-lacking AMPARs acutely has therapeutic effects on short-term working 
memory deficits. There were no significant differences between number of arm entries 
between groups. While IEM-1460 slightly improved context-dependent fear memory 
mutant mice, the effect was not significant enough to rescue it to WT-saline levels (Fig. 
5-1e. Two-way ANOVA, F6,129=2.819, interaction p=0.013). Although we did not observe 
a significant improvement in long-term fear memory in this study, it is possible that the 
effects of IEM-1460 on long-term memory will be more pronounced with a chronic 
treatment paradigm.  
IEM-1460 rescues latency to behavioral seizures after PTZ administration in R59X 
mice 
Finally, IEM-1460 rescued latency to seizure in mutant mice to WT saline levels, 
indicating that targeting GluA2-lacking AMPARs in CDD may attenuate hyperexcitability 
in the brain (Fig. 5-1f. One-way ANOVA, F3,36=4.621, p=0.0078). These data provide 
evidence to support the role of elevated GluA2-lacking AMPARs underlying deficits in 
memory, social behavior, and hyperexcitability in R59X mice. 
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Discussion 
 
Our treatment results indicate that the R59X model exhibits robust behavioral readouts 
in response to drug administration and could be used for future studies evaluating 
various treatment paradigms for CDD. Furthermore, they provide evidence for the 
therapeutic potential of both IEM-1460 and CBD in attenuating social and memory 
deficits as well as hyperexcitability in CDD. 
IEM-1460 significantly increased social interaction and attenuated working memory 
deficits and lowered seizure threshold in R59X mice. We have previously shown that 
administration of AMPAR blocker NBQX immediately following early-life seizures 
decreases development of social interaction deficits in rats. Although disturbances in 
GluA2 levels have been observed in autism and intellectual disability (Mignogna et al., 
2015; Achuta et al., 2018), this is the first time that a GluA2-lacking AMPAR-specific 
blocker has shown efficacy for deficits in social behavior and short-term memory. IEM-
1460 was not as effective in rescuing long-term contextual fear memory deficits in R59X 
mice—it increased % time freezing enough to be not significantly different than the WT 
vehicle treated mice but not significantly more than the R59X vehicle group. This 
suggests that perhaps a more chronic treatment paradigm with IEM-1460 would be 
effective in rescuing long-term memory deficits.  
Finally, IEM-1460 rescued latency to seizure in R59X mice to WT vehicle levels. To date 
no clinical trials have been conducted specifically with GluA2-lacking AMPAR blockers in 
patients with epilepsy, although perampanel, a general non-competitive AMPAR blocker, 
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has been approved to treat patients with epilepsy older than 12 years of age. IEM-1460 
is not currently an FDA approved drug, but has previously shown efficacy for reducing 
seizure severity in rodents (Gmiro et al., 2008; Szczurowska and Mareš, 2015). Our data 
adds to the sizeable literature reporting GluA2-lacking AMPAR dysregulation in autism 
(Lippman-Bell et al., 2013), intellectual disability (Mignogna et al. 2015; Achuta et al., 
2018), and epilepsy  (Grooms et al., 2000; Lippman-Bell et al., 2016), and supports 
development of GluA2-lacking AMPAR specific blockers for clinical trials.  
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Materials and Methods 
Effect of IEM-1460 on memory and social interaction 
12-16 week old mice were administered 10 mg/kg IEM-1460 (Tocris Biosciences) in 
0.9% saline or vehicle. Mice were tested 1 hour later for each behavioral test.  
Effect of IEM-1460 on seizure threshold 
18 week-old mice were administered 10 mg/kg IEM-1460 or vehicle followed one hour 
later by 40 mg/kg PTZ. Mice were placed in Plexiglass grid for video-monitoring. Videos 
were scored by blinded observer using a modified Racine scale as before  (Lüttjohann et 
al., 2009).  
Experimental design and statistical analysis 
For behavioral tests, the number of mice used in each experiment was predetermined 
before the start of the experiment and based on prior behavioral work in CDKL5 KO 
mice (Wang et al., 2012). 
Stastical analysis was completed using GraphPad Prism. All datasets were analyzed 
using the D’Agostino–Pearson test for normality. Datasets with normal distributions were 
analyzed for significance using unpaired Student’s two-tailed t test. One-way ANOVA 
and Two-way repeated-measures ANOVA were conducted for the appropriate datasets 
with Holm–Sidak’s multiple-comparison test. 
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Figures 
Figure 5-1 
 
 
Figure 5-1. Effect of GluA2-lacking AMPAR-specific blocker IEM-1460 on 
behavioral deficits in R59X mice. a, b. IEM-1460 rescues social behavior deficits in 
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CDKL5 R59X mice and increases direct interaction time. Two-way ANOVA with Sidak’s 
multiple comparisons test, interaction, p<0.0001 and ordinary one-way ANOVA with 
Sidak’s multiple comparisons test c. Olfactory function is not altered in CDKL5 R59X 
mice treated with IEM-1460. Two-way ANOVA, p=0.806 d. IEM-1460 rescues % SAB in 
CDKL5 R59X mice to WT levels. Ordinary one-way ANOVA with Sidak’s multiple 
comparisons test, p<0.0001 e. Drug treatment partially attenuates deficits in long-term 
fear memory. Two-way ANOVA with Sidak’s multiple comparisons test, interaction, 
p=0.013 f. Latency to first behavioral seizure after PTZ injection is rescued with 
pretreatment of IEM-1460. Ordinary one-way ANOVA, with Sidak’s multiple 
comparison’s test, p=0.0078. N=8-14 for all groups. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.  
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CHAPTER 6 – Therapeutic effects of cannabidiol in R59X mice 
Introduction 
Several patient groups for treatment-resistant early-life epilepsies have begun to treat 
pediatric patients with the natural compound cannabidiol (CBD), the major non-
psychoactive component of marijuana. Recently, this resulted in the first randomized, 
double-blind clinical trials showing efficacy in reducing seizures in several patient groups 
including those with Dravet Syndrome, Lennox-Gastaut Syndrome, and CDD  (Devinsky 
et al., 2018a, 2018b; Thiele et al., 2018). Beyond seizures, CBD has been reported to 
improve quality of life scores, which encompass improvements in sociability, memory, 
cognition, and other behavior (Rosenberg et al., 2017).  
The mechanism of action of cannabidiol in the brain is poorly understood. It has 
antagonist activity at G-protein coupled receptor 55 (GPR55) (Ryberg et al., 2007), 
which is predicted to mediate some of the anti-excitatory effects of CBD (Kaplan et al., 
2017; Gaston and Szaflarski, 2018).  
We hypothesized that CBD would have significant therapeutic effects in R59X mice 
similar to the human patients in CDD patients. Secondly, we predicted that GPR55 
would be upregulated in R59X mice given the difference in regulation of GluA2 in R59X 
mice. We also show that acute treatment of CBD results in significant therapeutic effects 
on social interaction, short-term memory, long-term memory and hyperexcitability in 
R59X mice. These intriguing findings suggest that CBD may be beneficial in improving 
patient quality of life not only because of its effects on hyperexcitability, but on other 
behaviors that affect patients’ day to day lives.  
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Results 
CBD attenuates memory and hyperexcitability deficits in R59X mice  
Given that CBD is currently being used to treat patients of CDD and other early-life 
epilepsy disorders (Devinsky et al., 2018a, 2018b; Thiele et al., 2018), we sought to 
examine whether CBD has therapeutic effects on behavior and seizure threshold in 
R59X mice. Dosing for behavioral tests was based on experiments performed in Dravet 
mice, which showed that the optimal dose in the social choice assay was 20 mg/kg and 
the optimal dose for reducing seizure severity was 100 mg/kg (Kaplan et al., 2017). 
Thus, we chose to use 20 mg/kg for all behavioral tests except for the seizure threshold 
assay where we administered 100 mg/kg. In the social choice assay, R59X mice treated 
with CBD spent significantly more time sniffing and investigating the novel mouse than 
vehicle-treated mutant mice, but it was still significantly less time compared to the WT 
vehicle group (Fig 6-1a., Two-way ANOVA, F3, 66= 14.04, interaction p<0.0001; R59X 
CBD vs R59X vehicle, p<0.01; R59X CBD vs WT vehicle, p<0.0001). There was no 
difference in direct interaction time between R59X CBD and R59X vehicle groups (Fig 6-
1b., One-way ANOVA with Sidak’s multiple comparisons, F3, 31= 17.51, p<0.0001; R59X 
CBD vs R59X vehicle, p=0.684). Interestingly, CBD significantly decreased the amount 
of time WT mice spent investigating the novel mouse in the cylinder (Fig 6-1a., WT CBD 
vs WT vehicle, p<0.01) as well as when the mouse was freely moving during the direct 
interaction portion (Fig 6-1b., WT CBD vs WT vehicle, p<0.05). Olfactory function was 
not altered between treatment groups (Fig 6-2c., Two-way ANOVA, interaction p=0.891). 
In the Y maze assay, CBD significantly improved % SAB in both WT and R59X mice 
(Fig. 6-2d. One-way ANOVA with Sidak’s multiple comparisons, F3, 33= 33.39, p<0.0001; 
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WT CBD vs WT vehicle, p<0.05; R59X CBD vs R59X vehicle, p<0.0001; R59X CBD vs 
WT vehicle, p=0.580), suggesting that it improves short-term working memory. 
Interestingly, in the context-dependent fear conditioning paradigm, CBD significantly 
improved fear memory on Day 2 only in R59X mice (Fig. 6-2e. Two-way ANOVA with 
Sidak’s multiple comparisons, F3, 102 = 4.738, main effect of treatment group, p=0.0039; 
R59X CBD vs R59X vehicle, p<0.05), providing evidence that CBD may have beneficial 
effects on both short and long-term memory in CDD. Finally, latency to seizure in R59X 
mice treated with CBD was rescued to WT vehicle levels (Fig. 6-2f. One-way ANOVA 
with Sidak’s multiple comparisons, F 3, 33 = 8.998, p=0.0002; R59X CBD vs R59X 
vehicle, p<0.001) suggesting that CBD may also have therapeutic effects on 
hyperexcitability in CDD.  
Expression of GPR55, a target of CBD, is not altered in R59X mice or in CDD 
patient samples 
CBD is reported to act as an antagonist at GPR55 (Ryberg et al., 2007), a G-protein 
coupled receptor that regulates intracellular calcium and neurotransmitter release 
(Sylantyev et al., 2013). Given the significant therapeutic effects of CBD in R59X mice, 
we investigated whether expression of GPR55 is increased in R59X and CDD patient 
samples. Expression of GPR55 is not significantly altered in cortex or hippocampus of 
R59X at any developmental time point or in CDD patient samples (Figure 6-2a-c). 
However, expression of GPR55 is regulated over development in the cortex and 
hippocampus of neurotypical controls, peaking in expression at approximately 10 years 
of age in the cortex and approximately 35 years of age in the hippocampus (Figure 6-
2d).  
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Discussion 
CBD significantly rescued latency to seizure in R59X mice to WT vehicle levels. 
Recently, preclinical and clinical studies have consistently reported therapeutic effects of 
CBD for seizures in treatment-resistant early life epilepsy (Kaplan et al., 2017; Devinsky 
et al., 2018a, 2018b; Thiele et al., 2018). Furthermore, one trial reported significantly 
decreased seizure events in patients with CDD (Devinsky et al., 2018). Patients stayed 
on previously prescribed anti-epileptic drugs during this trial, so some of the effects may 
be due to drug-drug interactions. Further preclinical studies are necessary to determine 
beneficial and adverse drug interactions with CBD, as well as optimal dosing strategies.  
Therapeutic effects of CBD in R59X mice extended beyond the lowered seizure 
threshold to deficits in memory and social interaction. CBD significantly improved social 
interaction in R59X mice, but not enough to rescue the deficit to WT vehicle levels. It 
also improved hippocampal-dependent short and long-term memory deficits in R59X 
mice. Children with autism treated with CBD were reported to have improved 
communication and behavior, which has led to several clinical and preclinical studies  
(Poleg et al., 2018). Indeed, CBD has previously shown efficacy for social deficits in a 
mouse model of Dravet syndrome (Kaplan et al., 2017). Furthermore, in a transgenic 
mouse model of Alzheimer’s Disease, CBD prevented development of social recognition 
memory deficits (Cheng et al., 2014). Finally, parent-reported observations on quality of 
life after CBD treatment in their children suggest that CBD may improve quality of life 
measures such as energy and fatigue, social interaction, memory, cognitive functions, 
and other behavior (Rosenberg et al., 2017). Our data showing social and memory 
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improvements in R59X mice provides additional evidence that CBD may be a successful 
therapeutic in cases of autism and intellectual disability.  
Expression of GPR55, a target of CBD, was not elevated in R59X tissue or CDD patient 
samples but it still may mediate therapeutic effects of CBD in CDD. CBD has been 
shown to increase inhibitory neurotransmission through antagonism of GPR55, and 
antagonists of GPR55 mimicked and occluded these effects of CBD on inhibitory 
neurotransmission in vitro (Kaplan et al., 2017). However, CBD has also been observed 
to have activity at several other proteins involved in neuronal excitability, including 
TRPV1 (Bisogno et al., 2001), T-type Ca2+ channels (Ross et al., 2008), and mutant 
sodium channels (Patel et al., 2016). Additionally, CBD is reported to modulate 
adenosine receptors, voltage-dependent anion selective channel protein (VDAC1), and 
release of tumor necrosis factor alpha (TNFa) (Devinsky et al., 2014). Given the number 
of purported targets of CBD and potential indirect effects on the endocannabinoid 
system itself via TRPV1 (Marzo and Petrocellis, 2012), it is difficult to speculate the 
exact mechanism by which CBD exerts therapeutic effects on seizures, memory, and 
social behavior in R59X mice. Furthermore, the relationship between CBD and GluA2-
lacking AMPARs has not been investigated and would be interesting to pursue.  
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Materials and Methods 
Effect of CBD on memory and social interaction 
12-16 week old mice were administered 20 mg/kg cannabidiol (Tocris) in 1:1:18 
ethanol:cremophore:saline or vehicle. Mice were tested 1 hour later for each behavioral 
test.  
Effect of CBD on seizure threshold 
18 week-old mice were administered 100 mg/kg cannabidiol (Tocris) in 1:1:18 
ethanol:cremophore:saline or vehicle followed one hour later by 40 mg/kg PTZ. Mice 
were placed in Plexiglass grid for video-monitoring. Videos were scored by blinded 
observer using a modified Racine scale as before  (Lüttjohann et al., 2009).  
Experimental design and statistical analysis 
For behavioral tests, the number of mice used in each experiment was predetermined 
before the start of the experiment and based on prior behavioral work in CDKL5 KO 
mice (Wang et al., 2012). 
Stastical analysis was completed using GraphPad Prism. All datasets were analyzed 
using the D’Agostino–Pearson test for normality. Datasets with normal distributions were 
analyzed for significance using unpaired Student’s two-tailed t test. One-way ANOVA 
and Two-way repeated-measures ANOVA were conducted for the appropriate datasets 
with Holm–Sidak’s multiple-comparison test. 
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Figures 
Figure 6-1 
 
Figure 6-1. Effect of experimental therapeutic CBD on behavioral deficits in R59X 
mice. a. R59X mice treated with CBD (20 mg/kg) display significantly more time 
interacting with the novel mouse than vehicle-treated R59X group, but are still 
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significantly less social than the WT vehicle group. Two-way ANOVA with Sidak’s 
multiple comparisons test, interaction, p<0.0001 b. CBD (20 mg/kg) does not rescue 
deficits in direct interaction in R59X mice, and significantly reduces the time WT mice 
spend interacting with novel mice. Ordinary one-way ANOVA with Sidak’s multiple 
comparisons test, p<0.0001 c. Olfactory function is not altered in R59X mice treated with 
CBD (20 mg/kg). Two-way ANOVA, p=0.891 d. CBD (20 mg/kg) increases % SAB in 
R59X mice to WT vehicle levels and significantly increases % SAB in WT mice. Ordinary 
one-way ANOVA with Sidak’s multiple comparisons test, p<0.0001 e. Acute CBD 
treatment (20 mg/kg) one hour before training and testing rescues deficits in long-term 
fear memory. Two-way ANOVA with Sidak’s multiple comparisons test, main effect of 
treatment group, p=0.0039 f. CBD (100 mg/kg) rescues latency to first behavioral 
seizure after PTZ injection in R59X mice. Ordinary one-way ANOVA, with Sidak’s 
multiple comparison’s test, p=0.0002. N=6-14 for all groups. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
  
100 
 
Figure 6-2 
 
Figure 6-2: Developmental expression of GPR55 in R59X and WT mice and human 
CDD and neurotypical cases. a. Expression of GPR55 is not significantly altered in 
R59X cortex at P7, P14, P21, or P50. N=6-10 for each time point. b. Expression of 
GPR55 is not significantly different in R59X hippocampus at P7, P14, P21, or P50. N=10 
for each time point. c. Expression of GPR55 does not appear to be dramatically altered 
in two CDD cases compared to age-matched neurotypical controls. N=2-3. d. 
Expression of GPR55 increases over human development and peaks at approximately 
10 years of age in the cortex and approximately 35 years of age in the hippocampus. 
N=2 per age.  
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CHAPTER 7 – Discussion  
Autism, intellectual disability, and seizures are key features of CDD and frequently co-
occur in neurodevelopmental disorders, suggesting common disease mechanisms of 
dysregulated synaptic structure and function (Eichler and Meier, 2008; Zoghbi and Bear, 
2012). There is currently no therapy that targets the core symptoms of CDD, which 
drove us to ask whether there are targetable synaptic alterations in the novel R59X 
mouse model of CDD that may contribute to disease pathogenesis. Here we found a 
specific dysregulation of membrane-bound GluA2-lacking AMPARs in R59X mice, and 
that targeting the activity of these receptors using IEM-1460, a specific antagonist of 
GluA2-lacking AMPARs, was effective in rescuing several core CDD phenotypes. 
Our results elucidate a critical molecular mechanism underlying hippocampal-associated 
learning and memory impairment and lowered seizure threshold in R59X mice. Mutant 
mice exhibit hyperactivity, impaired motor function and autistic-like deficits in social 
interaction, as well as impaired hippocampal-dependent learning and memory and 
lowered seizure threshold. In our molecular and functional analyses, we found evidence 
of increased synaptic GluA2-lacking AMPARs in the R59X hippocampus that was 
accompanied by elevated early-phase LTP. Finally, working memory and seizure 
threshold were rescued in the R59X mice by acute administration of a GluA2-lacking 
AMPAR open channel blocker, IEM1460. Together, these data reveal a GluA2-lacking 
AMPAR-specific mechanism of neurobehavioral deficits in R59X mice and may 
represent a potential therapeutic strategy for CDD.  
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NMDAR and AMPAR subunits are tightly regulated to mediate synaptic excitability and 
plasticity during critical periods of neuronal network formation in the brain. In particular, 
regulation of AMPAR subunit ratio GluA2:GluA1 determines levels of GluA2-lacking 
AMPARs at the synapse and resulting Ca2+ influx  (Jonas and Neuron, 1995), which has 
long-lasting effects on synaptic plasticity, neuronal growth, and gene transcription 
(Anggono and Huganir, 2012; Chater and Goda, 2014). During normal brain 
development, GluA2-lacking AMPARs are present postnatally during the critical period 
but decrease by adulthood. In contrast, the R59X mice exhibited unexpected persistence 
of GluA2-lacking AMPARs from P50 onwards. GluA2-lacking AMPAR dysregulation has 
been implicated in numerous disorders of E-I imbalance and autism (Lippman-Bell et al., 
2013; Mignogna et al., 2015; Achuta et al., 2018), and indeed the GluA2 deficits in R59X 
mice were accompanied by neurobehavioral deficits, elevated LTP, and seizure 
susceptibility. Furthermore, decreased GluA2:GluA1 was observed in two human cases 
of CDD, highlighting the potential clinical validity of Western blot results.  
Our whole cell patch clamp recordings levels expand upon our Western blot data and 
indicate that there is a physiologically relevant, increased population of GluA2-lacking 
AMPARs at hippocampal synapses. Inward rectification in the I-V plot, as observed in 
the R59X mice, is a hallmark characteristic of increased GluA2-lacking AMPARs due to 
their susceptibility to intracellular spermine block at high voltages (Rozov et al., 2012). 
GluA2-lacking AMPARs are also Ca2+-permeable (CP), unlike GluA2-containing 
AMPARs (Geiger et al., 1995), and elevated GluA2-lacking CP-AMPARs may cause 
hyperexcitability through elevated Ca2+ influx as well as increased NMDAR activation. 
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Additionally, increased Ca2+ influx through dysregulated GluA2-lacking AMPARs likely 
underlies enhanced early-phase LTP in R59X mice observed in our extracellular 
electrophysiology recordings.  
GluA2-lacking AMPARs are normally crucial for LTP induction and are inserted into the 
synaptic membrane immediately following HFS. Upon Ca2+ influx through GluA2-lacking 
AMPARs, GluA2 is released from intracellular stores by PICK1 and translocates to the 
synaptic membrane to form GluA2-containing AMPARs, which gradually replace GluA2-
lacking AMPARs at the synapse during the consolidation phase of LTP (40-60 min post-
HFS) (Plant et al., 2006; Jaafari et al., 2012; Hanley, 2014). The elevated potentiated 
response in R59X mice 15 min-post HFS is likely a result of increased Ca2+ influx due to 
1) elevated basal levels of GluA2-lacking CP-AMPARs at the synapse and 2) additional 
insertion of GluA2-lacking AMPARs that normally occurs during the induction phase of 
LTP. 
Furthermore, given that our earlier data suggests impaired transport of GluA2 to the 
membrane in R59X mice, it is possible that GluA2-containing AMPARs are hindered 
from being inserted into the membrane during the late-phase of LTP, causing the 
observed decay in the response. Our data from extracellular field recordings align with 
studies performed in hippocampal slices from GluA2 knock-out mice, showing that mice 
lacking the GluA2 subunit exhibited normal input-output function, PPR, and LTD along 
with elevated LTP  (Jia et al., 1996)  
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The behavioral effects observed in the R59X mice are similar to the CDKL5 KO mouse 
model that also exhibited hyperexcitability, deficits in motor coordination and social 
interaction, and impaired working and long-term memory (Wang et al., 2012). 
Furthermore hippocampal-dependent learning and memory impairments were observed 
in conditional knock-out mice where CDKL5 was selectively knocked out of forebrain 
excitatory neurons, emphasizing the importance of normal function of CDKL5 in 
excitatory hippocampal neurons  (Tang et al., 2017). Our observed increase in GluA2-
lacking AMPARs at hippocampal synapses combined with the functional and plasticity 
alterations at hippocampal synapses in R59X mice suggest an underlying mechanism 
for altered behavior at the whole animal level. Indeed, changes in GluA2 subunit levels 
and signaling have previously been linked to social interaction deficits  (Lippman-Bell et 
al., 2013) and learning and memory impairments (Wang et al., 2018; Zhou et al., 2018). 
Additionally, our lab has observed increased phosphorylation of calcium calmodulin-
dependent protein kinase II (CaMKII) at Thr286 and downstream genome-wide 
transcription factor methyl CPG binding protein 2 (MeCP2) at Ser421 as a result of Ca2+ 
influx through GluA2-lacking AMPARs  (Rosenberg et al., 2018). Although there is no 
change in total MeCP2 protein levels in mouse models of CDD  (Amendola et al., 2014), 
elevated phosphorylation of CaMKII and MeCP2 may be a downstream signaling 
mechanism by which increased GluA2-lacking AMPARs result in behavioral deficits and 
hyperexcitability observed in R59X mice. Indeed, CaMKII has been implicated in fear 
conditioning and spatial memory  (Wang et al., 2017) and increased CaMKII Thr286 
phosphorylation has been observed to cause seizures and ID in humans  (Akita et al., 
2018). Furthermore, mutations in MeCP2 are known to cause autism and Rett syndrome  
105 
 
(Amir et al., 1999) and MeCP2 Ser421 phosphorylation controls ability of MeCP2 to 
regulate dendritic growth and spine maturation  (Zhou et al., 2006). In R59X mice, these 
effector molecules may be causing chronic alterations in plasticity, excitability, and gene 
transcription due to increased Ca2+ influx through GluA2-lacking AMPARs. In future 
experiments, we aim to investigate alterations in gene expression and signaling 
pathways that may be downstream of elevated GluA2-lacking AMPARs in R59X mice. 
The GluA2-lacking AMPAR blocker IEM-1460 has previously been reported to increase 
latency to seizure after PTZ injection in rats at multiple ages. IEM-1460 also had age-
specific effects on seizure severity according to when expression levels of GluA2-lacking 
AMPARs were greatest in the brain  (Szczurowska and Mareš, 2015), as well as 
preventing seizure-induced phosphorylation of CAMKII and MeCP2 in immature rodents 
(Rosenberg et al., 2018). Our findings expand upon the therapeutic potential of IEM-
1460, demonstrating that selectively blocking GluA2-lacking AMPARs not only has 
beneficial effects on seizure threshold, but also on social interaction deficits and working 
memory. Our findings align with the lab’s previous work showing that AMPAR antagonist 
NBQX attenuates deficits in social preference following seizure-induced elevation of 
GluA2-lacking AMPARs in rats  (Lippman-Bell et al., 2013). Notably, the Jensen lab also 
showed a significant increase in synaptic GluA2-lacking AMPARs 48 hours post hypoxic 
seizures in rats that resulted in enhanced epileptogenesis later in life (Sanchez et al., 
2001; Rakhade et al., 2008; Lippman-Bell et al., 2013), suggesting that increased 
hippocampal GluA2-lacking AMPARs in R59X mice may be a targetable contributor to 
hyperexcitable circuit formation and behavioral alterations even in the absence of visible 
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seizures, and that blocking GluA2-lacking AMPARs with IEM-1460 may mitigate this 
process.  
Interestingly, acute administration of CBD also attenuated social deficits and rescued 
short and long-term memory in R59X mice to WT saline levels. Additionally, it increased 
latency to seizure behavior to WT levels. The mechanism of action of CBD is poorly 
understood, though it is reported to interact with GPR55, a protein implicated 
metabolism, motor coordination, cognitive functions, mediating sensory information, and 
activity of neurons and glia (Marichal-Cancinoa et al., 2017). GPR55 appears to mediate 
these effects through regulating intracellular Ca2+ influx (Laukner et al., 2008), though its 
activity is not fully understood. Recent data suggests that CBD antagonist activity at 
GPR55 increases inhibitory neurotransmission (Kaplan et al., 2018). However, CBD is 
also reported to interact with numerous other neuronal targets (Morales et al., 2017), 
which makes it challenging to postulate which pathways it may be affecting in R59X 
mice.  
Our experimental design focused on acute administration of both IEM-1460 and CBD to 
determine whether one dose was effective at providing therapeutic benefits. In future 
studies, it would be interesting to test both varying doses and chronic treatment 
paradigms, as well as whether early treatment results in later-life rescue of behavioral 
deficits. Our data supports further investigation of IEM-1460 and CBD in patients with 
CDD, not only for decreasing hyperexcitability but attenuating autistic behaviors and 
memory deficits as well.  
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